WO1993025197A1 - Compositions and methods for enhanced drug delivery - Google Patents

Compositions and methods for enhanced drug delivery Download PDF

Info

Publication number
WO1993025197A1
WO1993025197A1 PCT/US1993/005631 US9305631W WO9325197A1 WO 1993025197 A1 WO1993025197 A1 WO 1993025197A1 US 9305631 W US9305631 W US 9305631W WO 9325197 A1 WO9325197 A1 WO 9325197A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical agent
chemical
mmol
ester
dichloromethane
Prior art date
Application number
PCT/US1993/005631
Other languages
English (en)
French (fr)
Inventor
Ron L. Hale
Amy Lu
Dennis Solas
Harold E. Selick
Kevin R. Oldenburg
Alejandro C. Zaffaroni
Original Assignee
Affymax Technologies N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affymax Technologies N.V. filed Critical Affymax Technologies N.V.
Priority to AU45345/93A priority Critical patent/AU4534593A/en
Priority to EP93915319A priority patent/EP0647133A4/en
Publication of WO1993025197A1 publication Critical patent/WO1993025197A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Definitions

  • the present invention relates generally to methods for improving the transport and delivery of pharmaceutical agents across membranes. More particularly, the invention relates to methods for enhancing the transport and delivery of pharmaceutical agents through the addition of one or more chemical modifiers to the pharmaceutical agent.
  • parenteral administration is the most reliable means of delivering a pharmaceutical to a patient. See, Goodman et al . , Goodman and Gilman's Pharmacological Basis of Therapeutics, Pergamon Press, Elmsford, New York (1990) and Pratt et al . Principles of Drug Action: The Basis of Pharmacology, Churchill Livingstone, New York, New York (1990). Each parenteral mechanism insures that a prescribed dosage of the pharmaceutical agent is inserted into the fluid compartment of the body where it can be transported. The disadvantage of these modes of delivery is that they require an invasive procedure. The invasive nature of administration is inconvenient, painful and subject to infectious
  • Enteral and topical administration are more convenient, generally non-painful, and do not predispose to infection; however, both are limited.
  • the gastrointestinal and dermal surfaces present formidable barriers to transport and therefore, some pharmaceutical agents are not absorbed across these surfaces.
  • Another drawback to patient directed modes of administration is compliance. Pharmaceutical agents that have a short half-life require multiple daily doses. As the number of doses
  • the skin is an efficient barrier to the penetration of water soluble substances, and the rate of transdermal pharmaceutical agent absorption is primarily determined by the agent's lipid solubility, water solubility, and polarity.
  • This invention provides for methods of modifying a pharmaceutical agent comprising covalently bonding a charged chemical modifier, via a physiologically cleavable bond, to the pharmaceutical agent, such that the transport and/or delivery of the agent through membranes, or other biological or physical property of the agent, are enhanced.
  • the chemical modifier covalently bonded to the pharmaceutical agent forms a pharmaceutical agent-chemical modifier complex which is administered to a patient, wherein the chemical modifier is cleaved from the complex by a physiological process once the complex has been delivered, and the pharmaceutical agent is released within the patient in an active form.
  • One or more chemical modifiers is covalently bonded to the agent and the modifiers can be positively or negatively charged.
  • a functionality modifier will also be covalently bonded to the pharmaceutical agent-chemical modifier complex, optionally via a spacer group.
  • modifiers include taurine, betaine, carnitine, oligomeric carnitine, choline, lysine, polylysine, e-methylated lysine, oligomeric methylated lysine, other methylated amino acids, trigonelline, stachydrine, betonicine, histones, protamines, histones, nucleotide-based chemical modifiers, cytochrome c, squalamine, chonemorphine, conessine, and other bi- or multi-functional quaternary ammonium salts.
  • This invention provides for methods for the delivery of a pharmaceutical agent, comprising the steps of:
  • the complex has an enhanced delivery or transport rate through membranes over the pharmaceutical agent alone.
  • an iontophoretic drug delivery device is utilized and the complex is delivered through skin by applying an electric field.
  • an iontophoretic drug delivery device is utilized to delivery the complex through skin via application of an electric field.
  • compositions comprising a
  • This invention also provides a pharmaceutical formulation which comprises a
  • the invention also provides pharmaceutical agent compositions containing a pharmaceutical agent in a complex with one or more chemical modifiers such as taurine, betaine, carnitine, oligomeric carnitine, choline, lysine, polylysine, e-methylated lysine, oligomeric methylated lysine, other methylated amino acids, histones, protamines, nucleotide-based chemical modifiers, cytochrome c, squalamine, chonemorphine, conessine, and quaternary ammonium salts which are useful in enhancing pharmaceutical agent transport and delivery.
  • chemical modifiers such as taurine, betaine, carnitine, oligomeric carnitine, choline, lysine, polylysine, e-methylated lysine, oligomeric methylated lysine, other methylated amino acids, histones, protamines, nucleotide-based chemical modifiers, cytochrome c, squal
  • Some drugs are sold in an inactive form that is converted in vivo into a metabolite with
  • transdermal delivery refers to the transport and delivery, respectively, of a substance across the skin (i.e., transdermal), including the epidermis and dermis, or across a mucosal membrane (i.e., sublingual, buccal and vaginal), where the substance can contact, and be absorbed into, the capillaries. In certain instances, the transport and/or delivery of the substance across other membranes will be effected.
  • “Buccal delivery” refers to any system or device for the oral administration of a drug to a patient that is held in the mouth and is used to deliver a drug through the buccal mucosa and into the patient's body. This term includes, but is not limited to, lozenges, capsules, and tablets.
  • Enhanced delivery refers both to the facilitation of the delivery of a pharmaceutical agent and an absolute increase in the molar volume of the pharmaceutical agent transported per unit time through a constant surface area utilizing an equimolar pool of transported material as
  • Iontophoresis or “iontophoretic” refers to the introduction of an ionizable chemical through skin or mucosal membranes by the application of an electric field to the interface between the ionizable chemical compound and the skin or mucosal membrane.
  • Permeability refers to the ability 'of an agent or substance to penetrate, pervade, or diffuse through a barrier, membrane, or a skin layer, for example, between the cells of the stratum corneum and/or through the shunt pathways,
  • “Chemical modifier” refers to a charged molecule capable of covalently bonding to a pharmaceutical agent, another modifier, and/or a spacer group.
  • the term “chemical modifier” is meant to include both the charged molecule and its counterions, if any.
  • the covalent bond between the modifier and agent is preferably reversible and can be cleaved in vivo by biological or physiological processes which release the agent in an active form.
  • Space group refers to a molecule capable of covalently bonding simultaneously to both a pharmaceutical agent and a chemical modifier, optionally via another spacer group(s), and which does not necessarily carry a charge.
  • “Functionality modifier” refers to a molecule capable of covalently bonding to a pharmaceutical agent, a chemical modifier, or a spacer group, optionally via a spacer group(s), which does not necessarily carry a charge, and which serves to affect or modify a chemical, physical, or biological property of a pharmaceutical agent-chemical modifier complex, for example, providing a means for detection, for modifying the excretion half-life, for targeting, for increasing
  • the functionality modifier will carry a charge and thus, is also a chemical modifier.
  • “Pharmaceutical agent-modifier”, “pharmaceutical agent-modifier complex”, “pharmaceutical agent-chemical modifier”, or “pharmaceutical agent-chemical modifier complex” refers to at least one chemical modifier covalently bound, optionally via a spacer group, to a pharmaceutical agent.
  • Single or multiple chemical modifiers and according to some embodiments, single or multiple functionality modifiers, may be bound to a single pharmaceutical agent molecule to enhance the transport and delivery of the pharmaceutical agent.
  • the chemical modifiers may be bound to different sites on the pharmaceutical agent molecule, bound to other chemical
  • pharmaceutical agent-chemical modifier complex is meant to include both the charged molecule and any counterions. In other words, the net charge on the pharmaceutical agent-chemical modifier complex is zero.
  • Pharmaceutical agent-chemical modifier complexes may be schematically represented as pharmaceutical agent-[(spacer) x -(chemical modifier) y ] z or A-(S x -M y ) z wherein x is 0-10, y is 1-10 and z is 1-10 and A is the pharmaceutical agent, S is the spacer group, and M is the chemical modifier.
  • the pharmaceutical agent-chemical modifier complex will further comprise at least one functionality modifier.
  • Model compound refers to a compound which is relatively easy to synthesize and which can be used to
  • a model compound will comprise a "pharmaceutical agent”-chemical modifier complex in which the "pharmaceutical agent” is a substance not generally considered to be
  • “Chemical functionality” refers to a chemically reactive moiety or group on the pharmaceutical agent, spacer group, functionality modifier, and/or chemical modifier through which the covalent bonding occurs to form the
  • Penetration enhancer refers to a substance which is used to increase the transdermal or transmembrane flux of a compound. A penetration enhancer is typically applied to the skin or mucous membrane in combination with the compound.
  • Enhancers are believed to function by disrupting the skin or mucous membrane barrier or changing the partitioning behavior of the drug in the skin or mucous membrane.
  • Protecting group refers to a chemical group which generally exhibits the following characteristics: 1) the group must react selectively with the desired functionality in good yield to give a protected substrate that is stable to a future projected reaction; 2) the protecting group must be selectively removable from the protected substrate to yield the desired functionality; and 3) the protecting group must be removable in good yield by reagents that do not attack one or more of the other functional group (s) generated or present in the projected reaction. Examples of protecting groups can be found in Greene et al . Protective Groups in Organic Synthesis. 2nd Ed., John Wiley & Sons, New York (1991).
  • R may be a chemical modifier.
  • acyloxyalkylamide is -(CO)-NR'-CH rn R n -O(CO)- and an
  • R and R' may be chemical modifiers.
  • R and R' may be chemical modifiers.
  • R may be a chemical modifier.
  • R may be a chemical modifier.
  • R may be a chemical modifier.
  • R and R' may be chemical modifiers.
  • Acyloxyalkyl thioether refers to the group -SCH m R n - O(CO)- where R is hydrogen, alkyl, aryl, arylalkyl or
  • R may be a chemical modifier.
  • Aldehyde refers to the group -CHO.
  • R' or R may be a
  • Alkyl refers to a cyclic, branched, or straight chain alkyl group containing only carbon and hydrogen. This term is further exemplified by groups such as methyl, heptyl, (CH 2 ) 2 -, and adamantyl. Alkyl groups can either be
  • Non-interfering characterizes the substituents as not adversely affecting any reactions to be performed in accordance with the process of this invention.
  • R where R, R', and R" are independently hydrogen, alkyl, aryl, heteroaryl, or arylalkyl.
  • Amino refers to the group -NR'R", where R' and R" are independently hydrogen, alkyl, or aryl. If an amino group is to serve as a chemical functionality according to the present invention, either R' or R" must be hydrogen.
  • Anhydride refers to the group -(CO)-O-(CO)-.
  • Aryl or “Ar” refers to a monovalent unsaturated aromatic carbocyclic group having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl), which can optionally be unsubstituted or substituted with hydroxy, lower alkyl, alkoxy, chloro, halo, mercapto, and other non-interfering substituents.
  • Arylalkyl refers to the groups -R-Ar and -R-HetAr, where Ar is an aryl group, HetAr is a heteroaryl group, and R is straight-chain or branched-chain aliphatic group. Examples of arylalkyl groups include benzyl and furfuryl.
  • Carbonate refers to the group -O(CO)O-.
  • Carboxy or “carboxylic acid” refers to the group -COOH.
  • Disulfide refers to the group -SS-.
  • Ester refers to the group -(CO)O-R where R is alkyl, aryl, arylalkyl, or heteroaryl.
  • Heteroaryl or “HetAr” refers to a monovalent aromatic carbocyclic group having a single ring (e.g., pyridyl or furyl) or multiple condensed rings (e.g., indolizinyl or benzo[b]thienyl) and having at least one hetero atom, such as N, O or S, within the ring, which can optionally be
  • Heterocycle or “heterocyclic” refers to a monovalent saturated, unsaturated, or aromatic carbocyclic group having a single ring or multiple condensed ring and having at least one hetero atom, such as N, O, or S, within the ring, which can optionally be unsubstituted or substituted with hdyroxy, alkyl, alkoxy, halo, mercapto, and other non- interfering substituents.
  • nitrogen heterocycles include, but are not limited to, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine,
  • quinoxaline quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline,
  • Haldroxymethyl ketone ester refers to the group -(CO)-CH 2 -O-(CO)R where R is alkyl, aryl, arylalkyl or
  • R may be a chemical modifier.
  • Ketone or keto refers to the group
  • N-Mannich base refers to compounds formed through the reaction of amines with formaldehyde and certain reactive amide compounds. N-Mannich bases have moderate stability at acidic pH, but rapidly hydrolyse at physiological pH to liberate the free amino species. N-Mannich bases possess the group -NCH 2 N-.
  • N-acylamide refers to the group - (CO)-NR-(CO)- where R is hydrogen, alkyl, aryl, arylalkyl, or heteroaryl. R may be a chemical modifier.
  • Nucleotide refers to a phosphoric acid ester of a N-glycoside of a heterocyclic nitrogenous base and is meant to encompass both non-cyclic and cyclic derivatives.
  • phosphate can be present on position 2', 3', and/or 5".
  • glycoside component will be a pentose, however, in some embodiments, hexoses will be employed.
  • nitrogenous base typically will be selected from the group consisting of adenine, guanine, hypoxanthine, uraeil,
  • cytosine and thymine, and analogs or chemical modifications thereof.
  • Nucleotide-based pharmaceutical agent or “nucleotide-based drug” refer to a pharmaceutical agent or drug comprising a nucleotide, an oligonucleotide or a nucleic acid.
  • Nucleotide-based chemical modifier refers to a chemical modifier comprising a nucleotide, an oligonucleotide, or a nucleic acid.
  • Nucleic acid refers to either deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), whether single-stranded or double-stranded, and any chemical modifications thereof. Such modifications include, but are not limited to, alternate linkages other than the conventional phosphodiester linkage, modifications at cytosine exocyclic amines, substitution of 5-bromouracil, backbone modifications, base analogs,
  • methylations unusual base-pairing combinations, and the like.
  • alternate linkages include the methylphosphonates wherein one of the phosphorous-linked oxygens has been
  • N-sulfonylimidate refers to the group
  • R and R' are independently hydrogen, alkyl, aryl, arylalkyl or heteroaryl.
  • R and R' may be
  • sequences of nucleotides, joined by phosphodiester bonds, typically prepared by synthetic means Position 3' of each nucleotide unit is linked via a phosphate group to position 5' of the next unit. In the terminal units, the respective 3' and 5' positions can be free (i.e., free hydroxyl groups) or phosphorylated.
  • Those oligonucleotides employed in the present invention will vary widely in length. Suitable oligonucleotides can be prepared by the phosphoramidite method described by Beaucage and Carruthers, Tetra. Letts. 22: 1859-1862 (1981), or by the triester method according to Matteucci, et al . , J. Am. Chem. Soc., 103:3185 (1981), or by other methods, such as commercial automated oligonucleotide
  • Oligonucleotide also is meant to include chemical modifications of the naturally occurring
  • oligonucleotide skeleton Such modifications include, but are not limited to, modifications at cytosine exocyclic amines, substitution of 5-bromouracil, backbone modifications, base analogs, methylations, and the like.
  • Phosphate ester refers to a compound having the general formula RO(PO) (OR') (OR”), where R, R' and R" are independently selected from hydrogen, alkyl, aryl, arylalkyl, and heteroaryl.
  • Phosphodiester refers to a phosphate ester in which two hydroxyl groups of the phosphoric acid are
  • R'O-PO 2 H-OR where R' and R" are independently selected from the group consisting of hydrogen, alkyl, aryl, arylalkyl, or heteroaryl.
  • Oligonucleotides and nucleic acids are typically provided.
  • Phosphoramidate refers to a phosphodiester in which one or more of the hydroxyl groups is replaced with an amino group.
  • Quaternary ammonium salt refers to the positively charged group -N + R'R"R"', where R', R", and R'" are
  • R may be a chemical
  • Thioester refers to the group -(CO)S-R where R is alkyl, aryl, arylalkyl, or heteroaryl.
  • “Pharmaceutically or therapeutically effective dose or amount” refers to a dosage level sufficient to induce a desired biological result. That result may be the delivery of a pharmaceutical agent, alleviation of the signs, symptoms or causes of a disease or any other desired alteration of a biological system.
  • properties of the pharmaceutical agent that may be enhanced or altered using the methods of the present invention include its membrane transport rate, its delivery rate, its serum half-life, and its biodistribution, including the enhancement of its pharmacokinetic and pharmacodynamic
  • the methods described herein also will find use for decreasing the inflammation and/or irritation accompanying the delivery of. the pharmaceutical agent across membranes.
  • the methods of the present invention can be utilized to modify a pharmaceutical agent's ability to pass through the blood-brain barrier.
  • the agent's ability to transport through the placental barrier can also be altered using the compositions and methods described herein. Also provided are chemical modifiers that safely and
  • Preferred pharmaceutical agents that best can be modified for transmembrane transport are those effective at low concentrations, for example, less than 50 milligrams per day, or are topically administered. Marked improvements in pharmaceutical agent bioavailability can be expected for those pharmaceutical agents that are poorly absorbed enterally or undergo extensive first pass hepatic inactivation.
  • Pharmaceutical agents should possess (or be capable of being modified to possess) at least one chemical functionality that can be altered with chemical modifiers or that can be substituted with or otherwise covalently coupled to a charged group.
  • Preferred forms of chemical functionality include hydroxy, carboxy, amino, ketone, mercapto, sulfonamide, and amide groups.
  • Exemplary pharmaceutical agents or drugs that may be delivered by the system of the present invention include analgesics, anesthetics, antifungals, antibiotics,
  • antiinflammatories anthelmintics, antidotes, antiemetics, antihistamines, antihypertensives, antimalarials,
  • antimicrobials antipsychotics, antipyretics, antiseptics, antiarthritics, antituberculotics, antitussives, antivirals, cardioactive drugs, cathartics, chemotherapeutic agents, corticoids (steroids), antidepressants, depressants,
  • diagnostic aids diuretics, enzymes, expectorants, hormones, hypnotics, minerals, nutritional supplements,
  • parasympathomimetics potassium supplements, sedatives, sulfonamides, stimulants, sympathomimetics, tranquilizers, urinary antiinfectives, vasoconstrictors, vasodilators, vitamins, xanthine derivatives, and the like.
  • Examples of pharmaceutical agents with recommended dosage levels of less than 50 mg/day and thus, preferred for modification with chemical modifiers according to the present invention so as to improve the delivery and/or transport of the agents through membranes include the compounds set forth in Table 1.
  • Preferred examples of pharmaceutical agents include the digitalis drugs, such as digoxin, digitoxin, digoxigenin, and digitoxigenin. These drugs are all primarily used as cardiac agents. However, they differ widely in their digitalis drugs, such as digoxin, digitoxin, digoxigenin, and digitoxigenin. These drugs are all primarily used as cardiac agents. However, they differ widely in their digitalis drugs, such as digoxin, digitoxin, digoxigenin, and digitoxigenin. These drugs are all primarily used as cardiac agents. However, they differ widely in their digitalis drugs, such as digoxin, digitoxin, digoxigenin, and digitoxigenin. These drugs are all primarily used as cardiac agents. However, they differ widely in their digitalis drugs, such as digoxin, digitoxin, digoxigenin, and digitoxigenin. These drugs are all primarily used as cardiac agents. However, they differ widely in their digitalis drugs, such as digoxin, digitoxin, digoxigenin, and
  • Digoxin (3 ⁇ , 5 ⁇ , 12 ⁇ -3-[(O-2,6-dideoxy- ⁇ -D-ribo-hexopyranosyl(1 ⁇ 4)-O-2,6-dideoxy- ⁇ -D-ribo-hexopyranosyl-(1 ⁇ 4)-2,6-dideoxy- ⁇ -D-ribo-hexopyranosyl)oxy]-12,14-dihydroxycard-20(22)-enolide) and digitoxin (3 ⁇ ,5 ⁇ -3-[(O-2,6-dideoxy- ⁇ -D-ribo-hexopyranosyl(1 ⁇ 4)-O-2,6-dideoxy- ⁇ -D-ribo-hexopyranosyl-(1 ⁇ 4)-2,6-dideoxy- ⁇ -D-ribo-hexopyranosyl)oxy]-14-hydroxycard-20(22)-enolide) are two digitalis compounds available as pharmaceutical agents.
  • Both digoxin and digitoxin are glycosides with three digitoxose residues attached.
  • the amount of each compound absorbed depends largely on its polarity, which is a function of the net electronic charge on the molecule.
  • the nonpolar, lipophilic digitoxin is completely absorbed.
  • Other digitalis glycosides are not as well absorbed.
  • nonpolar digoxin is over 90% bound to tissue proteins. Digoxin also crosses both the blood-brain barrier and the placenta.
  • Digitoxin differs from the other commonly used digitalis glycosides not only in its firm binding to protein but also because it is metabolized in the liver, with the only active metabolite being digoxin.
  • the portion of digitoxin that is bound to protein is in equilibrium with free digitoxin in the serum.
  • Digitoxin is the most slowly secreted of the digitalis
  • Digoxin possesses five secondary hydroxyl and one tertiary hydroxyls, whereas digitoxin has four secondary and one tertiary hydroxyl groups.
  • the tertiary hydroxyl is not readily esterified.
  • one or more of the secondary hydroxyls may serve as a chemical functionality to form linkages to chemical modifiers or spacer groups.
  • Digoxigenin (3,12,14-trihydroxycard-20(22)-enolide) contains two secondary hydroxyls and digitoxigenin (3,14-dihydroxycard-20(22)-enolide) contains one secondary hydroxyl which may be used to form linkages with chemical modifiers or spacer groups.
  • digitoxigenin (3,14-dihydroxycard-20(22)-enolide) contains one secondary hydroxyl which may be used to form linkages with chemical modifiers or spacer groups.
  • Steroidal compounds form another preferred class of pharmaceutical agent.
  • Testosterone contains a single hydroxyl group, the 17 ⁇ -hydroxyl group, which may be used to form linkages with chemical modifiers or spacer groups.
  • Estradiol (estra-1,3,5(10)-triene-3,17 ⁇ -di1l) is also a preferred steroidal pharmaceutical agent. Estradiol and its ester derivatives are indicated for the treatment of symptoms of menopause and other conditions that cause a deficiency of endogenous estrogen production. The two
  • hydroxyl groups of estradiol serve as chemical functionalities for forming bonds with chemical modifiers or spacer groups.
  • Progesterone is also a preferred steroidal pharmaceutical agent. Progesterone is used primarily to suppress or synchronize estrus as well as to control habitual abortion and diagnose and treat menstrual disorders. The enone and ketone groups may be utilized to form bonds with chemical modifiers or spacer groups.
  • Additional preferred steroidal pharmaceutical agents include 3-hydroxy-5 ⁇ -pregnan-20-one (with a hydroxyl group and a ketone as chemical functionalities), 3- ⁇ -hydroxy-pregn-5-ene-20-one (with a hydroxyl and a ketone group as chemical functionalities), and related compounds. iv.
  • Nonsteroidal Anti-inflammatory Drugs Piroxicam (4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide) and indomethacin (1- (4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid) are nonsteroidal anti-inflammatory, analgesic, and antipyretic drugs used in the treatment of osteoarthritis and rheumatoid arthritis.
  • the phenolic hydroxyl group of piroxicam serves as a chemical functionality and can be linked to a chemical modifier or spacer group.
  • Indomethacin possesses a carboxy group as its chemical functionality.
  • Protein and peptide drugs may also be used as pharmaceutical agents according to the present invention.
  • the problems associated with conventional delivery strategies for protein and peptide drugs are widely appreciated. Oral administration of these drugs is generally impractical due to degradation and non-absorption in the gastrointestinal tract. Thus, the
  • parenteral route remains the principal delivery route.
  • Protein and peptide drugs are capable of either covalently binding to a chemical modifier and so can serve as pharmaceutical agents according to the present invention.
  • most protein and peptide drugs possess either an amino, carboxy, hydroxy, or mercapto group that can be used to bind covalently to a chemical modifier or spacer group.
  • protein and peptide drugs include those which contain either a cysteine or a lysine residue.
  • the mercapto group of cysteine and the e-amino group of lysine can be used as chemical functionality to bind to a chemical modifier or spacer group. See, also copending application Serial No.
  • protein and peptide drugs which are not amenable to coupling with a chemical modifier can be modified using recombinant DNA techniques. These modifications could entail the replacement of an existing amino acid of the drug with an amino acid or other group which can be easily coupled to a chemical modifier or the addition of amino acid(s) or other group(s) which can be easily coupled to a chemical modifier. In some instances, the net charge, charge distribution, or charge localization of the protein itself is modified using recombinant techniques (infra) thus, eliminating the necessity of additional bonding to a chemical modifier.
  • Amino acid-based drugs such as the cephalosporins, will typically have a molecular weight less than about 5000, and preferably, less than about 2500, and more preferably, less than about 1000.
  • Protein and peptide drugs typically have a molecule weight of at least about 100 daltons, and more typically a molecular weight in the range of about 200 to 40,000 daltons. Specific examples of peptides and proteins in this size range include, but are not limited to, those found in Table 2.
  • Calcitonin e.g., eel, Bradykinin potentiator B
  • Endorphin alpha, beta, and Cystic fibrosis transmembrane gamma conduct regulator (CFTR)
  • Pituitary hormones e.g., stimulating factor
  • HGH HGH, HMG, HCG, desmopressin filgrastim. (G-CSF)
  • GM-CSF aANF growth factor releasing sargramostrim.
  • GFRF GFRF Multilineage colony
  • CSF Melanocyte-stimulating stimulating factor
  • CSF-4 Somatostatin Colony stimulating factor 4 Bradykinin
  • EGF Somatotropin Epidermal growth factor
  • Interferons e.g., alpha, Heparin binding neurotrophic beta, and gamma factor (HBNF)
  • Interleukins e.g., IL-1 Fibroblast growth factor receptor antagonist; (FGF)
  • IL-10 IL-10
  • CSIF cytokine Hirudin
  • Urofollitropin Follicle Macrophage-derived neutrophil stimulating hormone, FSH
  • LH-releasing hormone Melatonin, tryptophan
  • MK Midkine
  • TPA Insulin-like growth factors
  • Thyroid stimulating hormone Pentigetide Thyroid stimulating hormone Pentigetide
  • the protein or peptide drug is one of the highly related sequences of alpha interferon 2 (IFN- ⁇ 2).
  • IFN- ⁇ 2a (sold by Roche as Roferon A)
  • INF- ⁇ 2b (sold by Schering as Intron A) are 19 kilodalton (kDa) proteins of 165 amino acids. These proteins contain two pairs of disulfide linked cysteines and include 20 basic and 22 acidic residues for a net positive charge of approximately -1.69 at neutral pH. IFN has been used as an
  • carcinoma hairy cell leukemia, Kaposi's sarcoma, melanoma, and T-cell lymphoma, as well as an antiviral agent in the treatment of non-A,B-hepatitis, genital warts, Epstein-Barr virus, CMV, AIDS, and rhinovirus.
  • parathyroid hormone is a linear polypeptide having a specific biological function as a pharmaceutical agent.
  • PTH parathyroid hormone
  • PTH Parathyroid Hormone and Thyrocalcitonin (Calcitonin), R. V. Talmage, et al . , Eds. Excerpta Medica, New York (1968).
  • the sequence of the polypeptide varies slightly among mammalian species.
  • PTH is meant to include human parathyroid hormone, as well as the other variants and the 34 amino acid fragment.
  • PTH contains a variety of chemical functionalities (e.g., hydroxyl groups from serine residues, carboxylic acid groups from aspartic acid residues, and amino groups from glutamine, lysine, and arginine residues) which may potentially be used to bind to chemical modifiers.
  • PTH serves as a regulatory factor in the homeostatic control of calcium and phosphate metabolism. See, e.g.,
  • PTH has also been used as a blood calcium regulator.
  • Calcitonin is also a preferred peptide
  • Calcitonin is a polypeptide containing 32 amino acid residues. See Harper et al . , Eds., Review of
  • amino acid sequence differs among mammalian and fish species. According to the present
  • calcitonin is meant to include all calcitonin, including that of humans, mammals, and fish, as well as other variants. Calcitonin contains several chemical
  • Calcitonin is a calcium regulating hormone and has been used in the treatment of osteoporosis, hypercalcemia, and Paget's disease.
  • cytokine IL-10 is produced by the TH2 helper subset, B cell subsets and LPs-activated monocytes.
  • IL-10 inhibits several immune functions that are relevant to the skin immune response and thus, the development of the irritation and inflammation that is sometimes associated with the transdermal or
  • the present invention also contemplates the simultaneous or sequential transdermal, either passively or iontophoretically, delivery of a drug that elicits inflammation or irritation with a pharmaceutical agent-chemical modifier complex wherein the pharmaceutical agent is IL-10, or an analog thereof.
  • the complex is delivered in an amount sufficient to prevent the inflammation and irritation generally associated with delivery of the other drug.
  • G-CSF a colony stimulating factor that stimulates production of granulocytes, particularly neutrophils
  • GM-CSF a colony stimulating factor that stimulates production of granulocytes/macrophages/ monocytes
  • human growth factor insulin, a hormone (protein) naturally secreted by the ⁇ cells of the pancreas (when stimulated by glucose and the parasympathetic nervous system); antibodies (subfragments); EPO, a glycoprotein hormone
  • Vasotec ® a antihypertensive (Enalapril maleate, Merck, Sharp & Dohme, West Point, PA); Capoten ® , a antihypertensive
  • Rocephin ® an antiinfective (ceftriaxone sodium, Roche);
  • Augmentin ® an antiinfective (Smith Kline & French
  • Ceclor ® an antiinfective (Cefaclor, 3-chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid, Eli Lilly and Company, Indianapolis, IN);
  • Sandimmune ® an immunosuppressive (cyclosporine, a cyclic polypeptide consisting of 11 amino acids, Sandoz
  • Premaxin ® an antiinfective (Imipenem-cilastatin sodium, Merck); Fortaz ® , an antiinfective (ceftazidime, Glaxo Pharmaceuticals, Research Triangle Park, NC); Amoxil, an antiinfective (amoxicillin, Beecham Laboratories, Bristol, TN); Humulin ® , an antidiabetic (human insulin recombinant DNA origin, Lilly); Epogen ® , an erthyropoiesis enhancer (Epoetin alfa, a 165 amino acid glycoprotein manufactured by recombinant DNA technology with the same biological effects as endogenous erythropoietin, Amgen Inc., Thousand Oaks, CA); and Procrit ® , an antiinfective (Imipenem-cilastatin sodium, Merck); Fortaz ® , an antiinfective (ceftazidime, Glaxo Pharmaceuticals, Research Triangle Park, NC); Amoxil,
  • Aptamers are single- or double-stranded DNA or single-stranded RNA molecules that bind specific molecular targets.
  • aptamers function by inhibiting the actions of the molecular target, e.g.,
  • molecular targets will be capable of forming non-covalent but specific associations with aptamers, including small molecules drugs, metabolites, cofactors, toxins, saccharide-based drugs, nucleotide-based drugs, glycoproteins, and the like
  • the molecular target will comprise a protein or peptide, including serum proteins, kinins, eicosanoids, cell surface molecules, and the like.
  • aptamers include Gilead's antithrombin inhibitor GS 522 and its derivatives (Gilead Science, Foster City, CA). See also Macaya et al . (1993) Proc. Natl. Acad. Sci. USA 90:3745-9; Bock et al . (1992) Nature (London)
  • Aptamers specific for a given biomolecule can be identified by using techniques known in the art. See, e . g . , Toole et al . (1992) PCT Publication No. WO 92/14843; Tuerk and Gold (1991) PCT Publication No. WO 91/19813; Weintraub and Hutchinson (1992) PCT Publication No. 92/05285; and Ellington and Szostak (1990) Nature 346:818. Briefly, these techniques typically involve the complexation of the molecular target with a random mixture of oligonucleotides. The aptamermolecular target complex is separated from the uncomplexed oligonucleotides. The aptamer is recovered from the separated complex and amplified. This cycle is repeated to identify those aptamer sequences with the highest affinity for the molecular target.
  • Antisense compounds are single stranded DNA or RNA oligonucleotides that are designed to bind and disable or prevent the production of the mRNA responsible for generating a particular protein. Antisense compounds complementary to one or more sequences are employed to inhibit transcription, RNA processing, and/or translation of the cognate mRNA species and thereby effect a reduction in the amount of the respective encoded polypeptide.
  • Antisense compounds can provide a therapeutic function by inhibiting in vivo the formation of one or more proteins that cause or are involved with disease.
  • Antisense compounds complementary to certain gene messenger RNA or viral sequences have been reported to inhibit the spread of disease related to viral and retroviral infectious agents (See, for example, Matsukura et al . (1987) Proc. Natl. Acad. Sci. USA 84:7706, and references cited therein).
  • oligonucleotides can bind to duplex DNA via triple helix formation and inhibit
  • Triple helix compounds are oligonucleotides that bind to sequences of double-stranded DNA and are intended to inhibit selectively the transcription of disease-causing genes, such as viral genes, e.g., HIV and herpes simplex virus, and oncogenes.
  • nucleotide-based drugs have had limited success as therapeutic agents, in part, because of problems associated with their stability and delivery.
  • Nucleotide-based pharmaceutical agents contain a phosphodiester bond which is sensitive to degradation by nucleases.
  • oligonucleotide or nucleic acid as a pharmaceutical agent that depends upon the integrity of the sequence for its recognition specificity.
  • naturally occurring oligonucleotides and nucleic acids often must be chemically modified to render them resistant to nucleases which would degrade them in vivo , or even in vitro unless care is taken to choose appropriate conditions.
  • nucleotide-based drugs of the present invention will have a molecular weight greater than about 350.
  • nucleotide-based drugs include di- and trinucleotides, such as GS 375, a dinucleotide analog with potential therapeutic activity against the influenza virus (Gilead Sciences, Inc., Foster City, CA), antisense compounds, and triple helix drugs.
  • Antisense compounds include antisense RNA or DNA, single or double stranded, oligonucleotides, or their analogs, which can hybridize specifically to individual mRNA species and prevent transcription and/or RNA processing of the mRNA species and/or translation of the encoded polypeptide (Ching et al . Proc. Natl. Acad. Sci. U.S.A. 86:10006-10010 (1989); Broder et al . Ann. Int. Med. 113:604-618 (1990); Loreau et al . FEBS Letters 274:53-56 (1990); Holcenberg et al . W091/11535; U.S.S.N. 07/530,165 ("New human CRIPTO gene"); WO91/09865;
  • Triple helix drugs are oligonucleotides that stop protein
  • oligonucleotides e.g., antisense compounds and triple helix drugs
  • antisense compounds and triple helix drugs also can include nucleotide substitutions, additions, deletions, or transpositions, so long as specific
  • oligonucleotide hybridization to the relevant target sequence is retained as a functional property of the oligonucleotide.
  • some embodiments will employ phosphorothioate analogs which are more resistant to degradation by nucleases than their
  • Phosphoramidate derivatives of oligonucleotides also are known to bind to complementary polynucleotides and have the additional capability of.
  • the antisense compounds and triple helix drugs will comprise O-methylribonucleotides (EP Publication No. 360609). Chimeric oligonucleotides may also be used (Dagle et al . (1990) Nucleic Acids Res. 18: 4751).
  • antisense oligonucleotides and triple helix may comprise polyamide nucleic acids (Nielsen et al . (1991) Science 254:1497 and PCT publication No. WO 90/15065) or other cationic derivatives (Letsinger et al . (1988) J. Am. Chem.
  • oligonucleotides wherein one or more of the phosphodiester linkages has been substituted with an isosteric group, such as a 2-4 atom long internucleoside linkage as described in PCT publication Nos. WO 92/05186 and 91/06556, or a formacetal group (Matteucci et al . (1991) J. Am. Chem. Soc. 113:7767-7768) or an amide group (Nielsen et al . (1991) Science
  • nucleotide analogs for example wherein the sugar or base is chemically modified, can be employed in the present invention.
  • "Analogous" forms of purines and pyrimidines are those generally known in the art, many of which are used as chemotherapeutic agents.
  • An exemplary but not exhaustive list includes 4-acetylcytosine,
  • 5-fluorouracil 5-bromouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethylaminomethyluracil, dihydrouracil, inosine, N 6 -isopentenyladenine, 1-methyladenine,
  • N-uracil-5-oxyacetic acid methylester N-uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), pseudouracil, queosine, 2-thiocytosine, and
  • the conventional bases by halogenated bases.
  • the 2'-furanose position on the base can have a non-charged bulky group substitution.
  • non-charged bulky groups include branched alkyls, sugars and branched sugars.
  • Terminal modification also provides a useful procedure to modify cell type specificity, pharmacokinetics, nuclear permeability, and absolute cell uptake rate for oligonucleotide pharmaceutical agents. For example,
  • substitutions at the 5' and 3' ends include reactive groups which allow covalent crosslinking of the nucleotide-based pharmaceutical agent to other species and bulky groups which improve cellular uptake.
  • Oligodeoxynucleotides Antisense Inhibitors of Gene Expression, (1989) Cohen, Ed., CRC Press; Prospects for Antisense Nucleic Acid Therapeutics for Cancer and AIDS, (1991), Wickstrom, Ed., Wiley-Liss; Gene Regulation: Biology of Antisense RNA and DNA, (1992) Erickson and Izant, Eds., Raven Press; and Antisense RNA and DNA,
  • Antisense polynucleotides of various lengths may be delivered, although such antisense polynucleotides typically comprise a sequence of at least about 15 consecutive
  • the triple helix drug will comprise a DNA oligonucleotide in the range of about 20 to 40 bases.
  • Heterocyclic drugs and particularly those containing at least one nitrogen heterocyclic ring can be employed as pharmaceutical agents in the methods described herein.
  • yohimbine is an indole alkaloid that blocks ⁇ -2-adrenergic receptors. Its peripheral effects are to increase cholinergic activity at the same time that it decreases adrenergic activity. This combination has led to the use of yohimbine in the treatment and diagnostic
  • Yohimbine the methyl ester of yohimbic acid, possesses a free hydroxyl group which may serve as the necessary chemical functionality for binding to a chemical modifier or spacer group.
  • Yohimbic acid which contains both a free hydroxyl group and a carboxy group as potential chemical
  • Morphine (7,8-didehydro-4,5-epoxy-17-methyl-(5 ⁇ ,6 ⁇ )-morphinan-3,6-diol sulfate (2:1), pentahydrate) is the most important alkaloid of opium. Morphine exerts its primary effect on the central nervous systems and organs containing smooth muscle. Morphine, as other opiods, acts as an agonist interacting with stereospecific and saturable binding
  • the central nervous system effects of intravenously administered morphine sulfate are influenced by its ability to cross the blood-brain barrier.
  • the delay in the onset of analgesia following epidural or intrathecal injection may be attributed to its relatively poor lipid solubility (i.e., an oil/water partition coefficient of 1.42) and its slow access to the receptor sites.
  • the hydrophilic character of morphine may also explains its retention in the central nervous system and its slow release into the systemic circulation.
  • the introduction of a charged chemical modifier should effectively prevent morphine from crossing the blood-brain barrier.
  • the morphine-chemical modifier complex should serve as a peripheral acting analog.
  • Morphine possesses two hydroxyl groups which can be coupled to chemical modifiers.
  • Methotrexate (formerly Amethopterin, N-[4-[[(2,4-diamino-6-pteridinyl)-methyl]methylamino]benzoyl]-L-glutamic acid) is an antimetabolite used in the treatment of certain neoplastic diseases, severe psoriasis, and adult rheumatoid arthritis. Methotrexate inhibits dihydrofolic acid reductase and therefore interferes with DNA synthesis, repair, and cellular replication. Methotrexate possesses several chemical functionalities, including carboxy groups and amino groups, which can be bound to chemical modifiers according to the present invention.
  • Lorazepam (7-chloro-5-(o-chlorophenyl)-1,3-dihydro- 3-hydroxy-2H-1,4-benzodiazepin-2-one) is a benzodiazepine with antianxiety and sedative effects.
  • the mean half-life for lorazepam is about 16 hours when given intravenously or intramuscularly. Lorazepam is rapidly conjugated at the 3-hydroxyl group into its major metabolite, lorazepam
  • Lorazepam possesses a free hydroxyl group and an amino group which can be derivatized according to the methods described herein.
  • 6-Mercaptopurine (1,7-dihydro-6H-purine-6-thionemonohydrate) is one of large series of purine analogues which interfere with nucleic acid biosynthesis and has been found active against human leukemias. See, e . g. , Hitchings and Elion (1954) Ann. NY Acad. Sci. 60:195-199. Clinical studies have shown that the absorption of an oral dose of
  • 6-Mercaptopurine contains a free mercapto group and an amino group for bonding to chemical modifiers.
  • 5-Fluorouracil is another preferred pharmaceutical agent.
  • 5-Fluorouracil (5-fluoro-2,4 (1H, 3H) -pyrimidinedione) is an antineoplastic antimetabolite.
  • fluorouracil interferes with the synthesis of DNA and to a lesser extent inhibits the formation of RNA.
  • Fluorouracil distributes into tumors, intestinal mucosa, bone marrow, liver, and other tissues throughout the body. In spite of its limited lipid solubility, fluorouracil diffuses readily across the blood-brain barrier. Fluorouracil is effective in the palliative management of carcinoma of the colon, rectum, breast, stomach, and pancreas. Fluorouracil possesses two amino groups which can bond to chemical
  • Another preferred heterocyclic drug is theophylline, a xanthine bronchodilator, pulmonary vasodilator, and smooth muscle relaxant.
  • Theophylline is used for the symptomatic relief and/or prevention of asthma and the reversible
  • Theophylline possesses an amino functionality for coupling with a chemical modifier.
  • Nalidixic acid is also a heterocyclic drug which can be delivered using the methods described herein.
  • Nalidixic acid is an antibacterial agent with activity against gram negative bacteria and is rapidly absorbed from the
  • Nalidixic acid possesses an amino group, a keto group, and a carboxy group as chemical
  • Melatonin a tryptamine derivative, is a hormone of the pineal gland and is also produced by extrapineal tissues. melatonin has been postulated as the mediator of photic-induced antigonadotrophic activity in photoperiodic mammals. Melatonin has been used in the treatment of psychiatric disorders. Melatonin possesses amino functionality for coupling with chemical modifiers.
  • Nicotinic acid or niacin functions in the body as a component of two hydrogen transporting coenzymes. In addition to its functions as a vitamin, nicotinic acid exerts several distinctive pharmacological effects which vary according to the dosage level employed. Nicotinic acid, in large doses, causes a reduction in serum lipids. Nicotinic acid is a nitrogen heterocycle having a hydroxyl group.
  • the chemical modifier is preferably susceptible to in vivo cleavage from the pharmaceutical agent-chemical modifier complex, such that the agent is in an active form and the modifier becomes a non-toxic compound or is rapidly degraded.
  • the modifier will be a naturally occurring substance.
  • the modifier is a biologically-active molecule or a second pharmaceutical agent.
  • Chemical modifiers according to the present invention, comprise either permanently charged organic radicals
  • the net ionic charge of a chemical modifier is a chemical modifier
  • chemical modifiers function primarily to alter the charge characteristics of a pharmaceutical agent (e.g., by the addition, deletion, or redistribution of
  • more than one chemical modifiers can be coupled to a charged pharmaceutical agent to produce a complex having the same net charge as the pharmaceutical agent, but exhibiting different water or lipid solubility due to the introduction of the additional hydrophilic or lipophilic groups of the chemical modifiers.
  • Chemical modifiers possess at least one chemical functionality which can be covalently bonded to a
  • the chemical modifier carries a positive charge.
  • the positive charge typically arises by virtue of covalent bonds, such as in a quaternary ammonium group.
  • the charged complex is prepared by the covalent attachment of an uncharged moiety in such a manner as to generate a charge.
  • the complex can be dissociated under physiological conditions.
  • an ⁇ -haloalkyl carbonates or esters can be reacted with a pharmaceutical agent having a tertiary amino group to provide a pharmaceutical agent-chemical modifier complex having a quaternary ammonium group.
  • Chemical or enzymatic hydrolysis of the carbonate or ester bond is
  • the pharmaceutical agent comprises deprenyl, as illustrated below:
  • the chemical modifier acquires a positive charge only after the modifier is
  • the pharmaceutical agent-chemical modifier complex may obtain a positive charge via protonation in the delivery buffer or formulation due to the pH conditions which exist during drug delivery. iii. Examples of Chemical Modifiers
  • choline (2-hydroxy-N,N,N-trimethylethanaminium, available from Aldrich Chemical Co., Milwaukee, Wisconsin). Choline carries a positive charge and possesses a hydroxyl group as a chemical functionality. The hydroxyl group may be utilized, for example, to form ester or carbonate linkages with carboxy or hydroxyl groups,
  • Homologs of choline such as 3-hydroxy-N,N,N-trimethylpropaminium
  • chloride may also serve as chemical modifiers.
  • homologs of choline differ from choline in the number of carbon atoms. Like choline, homologs of choline possess both a hydroxyl group .and an amino group as chemical functionality.
  • Carnitine (3-carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium hydroxide, inner salt
  • Carnitine possesses two types of chemical functionality with which it can bond to a pharmaceutical agent.
  • the hydroxyl of carnitine may be reacted with a carboxy group of a pharmaceutical agent.
  • carboxy group of carnitine may be utilized to form, for example, either ester, thioester, or amide linkages with hydroxy, mercapto, or amino groups of a
  • Homologs of carnitine such as 4 ,4-dimethylamino-3-hydroxybutyric acid or 6, 6-dimethylamino-3-hydroxyhexanoic acid, may also serve as chemical modifiers.
  • the dimethylamino group of these chemical modifiers can be alkylated to form a quaternary ammonium salt either before or after the chemical modifier is coupled to a pharmaceutical agent.
  • These homologs of carnitine differ from carnitine in their number of carbon atoms. Like carnitine, homologs of carnitine possess both a hydroxyl group and a carboxy group with which they can form bonds to pharmaceutical agents.
  • Oligomers of carnitine may also be employed as chemical modifiers.
  • the molecular weight of the oligomer is usually between 100-2000. Typically 2 to 10 carnitine molecules are used to construct the polyester.
  • a further carnitine derivative which may function as a chemical modifier is thiocarnitine.
  • Thiocarnitine is the mercapto analog to carnitine and thus, possesses a mercapto group and a carboxylic acid group as chemical functionality.
  • Lysine (2,6-diaminohexanoic acid, available from Aldrich Chemical Co.) and particularly its N ⁇ -methylated homologs, especially N ⁇ -trimethyllysine, may also be used as chemical modifiers.
  • lysine shall be understood to refer to lysine and to its N ⁇ -methylated homologs, including N ⁇ -trimethyllysine and its ⁇ -hydroxyl derivative.
  • lysine possesses two functionalities with which it can bind to a pharmaceutical agent. Specifically, either the amino or carboxy groups of lysine may be exploited to form linkages with pharmaceutical agents.
  • the amino group for example, may be converted to an amide through reaction with a carboxy group of the pharmaceutical agent or to a carbamate by reaction with the chloroformate derivative of a hydroxy-containing pharmaceutical agent.
  • the carboxy group of lysine may be transformed into either an ester, thioester or amide through reaction with a hydroxy, mercapto, or amino group of a pharmaceutical agent.
  • derivatives of lysine may be used as chemical modifiers.
  • the chemical modifier which provides a third functionality for selective modification may be used as a chemical modifier.
  • the chemical modifier exhibits therapeutic effects apart from its carrier function.
  • An example of a therapeutic chemical modifier is oligomeric or polymeric lysine (polylysine).
  • Polylysine possesses antiviral and antibacterial activities, as well as a specific affinity for tumor cells in cancerous tissue. Ryser, H.J.-P. and Shen, W.-C. (1986) in "Targeting of Drugs with Synthetic Systems," G. Gregoriadis, J. Senior and G. Poste, Eds., pp. 103-121, Plenum Publishing Corp. New York.
  • Polylysine has also been shown to enhance the uptake into cells of conjugated proteins such as albumin and peroxidase. Shen, W.-C. and Ryser, H.J.- P, (1978) Proc. Natl. Acad. Sci. USA 75:1872-1876.
  • poly(L-lysine) contains amino and carboxy groups. Typically, 2 to 10 lysines are used to form the polyamide. The molecular weight of the oligomer is usually between 200-2000. The polymerization of lysine may be accomplished by methods well known by those skilled in the art.
  • polylysine derivatives containing specific protease cleavage sites may serve as chemical
  • amino acids such as ornithine (2,5-diaminopentanoic acid, available from Aldrich Chemical Co.) and its N ⁇ -methylated homologs, serine, threonine, and
  • tyrosine may also be used as chemical modifiers in an
  • folate or folic acid N-[4-[[2(2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
  • folic acid N-[4-[[2(2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
  • Folate Is internalized by cells by receptor-mediated endocytosis and it has been reported that covalently conjugating folic acid to a macromolecule, such as BSA, bovine IgG, bovine RNase, and horseradish peroxidase, allows for the delivery of the conjugates into many living cells by the cellular uptake system for folate. See Leamon and Low (1991) Proc. Natl. Acad. Sci. USA 88:5572-5576 and Anderson et al . (1992) Science 255:410-411.
  • a macromolecule such as BSA, bovine IgG, bovine RNase, and horseradish peroxidase
  • betaine (1-carboxy-N,N,N-trimethylmethanaminium hydroxide inner salt, available from Aldrich Chemical Co.).
  • Betaine possess a carboxylic acid as chemical functionality and carries a permanent positive charge from the quaternary ammonium group.
  • Homologs of betaine such as N,N,N-trimethyl-4-aminobutyric acid may also serve as chemical modifiers.
  • Other preferred chemical modifiers include betonicine (trans-2-carboxy-4-hydroxy-1,1-dimethylpyrrolidinium hydroxide, inner salt), stachydrine (2-carboxy-1, 1-dimethylpyrrolidinium hyroxide inner salt), and trigonelline (3-carboxy-1-methylpyridinium hyroxide inner salt).
  • betonicine trans-2-carboxy-4-hydroxy-1,1-dimethylpyrrolidinium hydroxide, inner salt
  • stachydrine (2-carboxy-1, 1-dimethylpyrrolidinium hyroxide inner salt
  • trigonelline (3-carboxy-1-methylpyridinium hyroxide inner salt).
  • ammonium group as well as chemical functionality capable of coupling to pharmaceutical agents.
  • histones include histones. Several classes of these highly conserved proteins exist. The smallest histone is H4 with 103 amino acids and a net charge of approximately +18 at neutral pH. The largest histone H1 carries a charge of approximately +46 at neutral pH over approximately 207 residues. Histone H1 is rich in lysine groups. These lysine groups contain amino groups which may be used to bind to pharmaceutical agents or spacer groups.
  • Histones H2A and H2B also contain lysine groups, and thus, amino groups as chemical functionality.
  • Histones H3 and H4 are rich in arginine.
  • the arginine residue provides an amino group which may be bonded to spacer groups or pharmaceutical agents.
  • one variant of the histone H3 contains a free cysteine residue that may be used to couple with spacer groups or pharmaceutical agents.
  • the protamines are a group of proteins that contain basic amino acids and can serve as chemical modifiers.
  • Anther lysine rich protein which can be employed as chemical modifiers according to the methods described herein is cytochrome c, a heme protein in which the active prosthetic group is a derivative of iron protoporphyrin IX. Cytochrome c occurs in the cells of all aerobic organisms and can be found in animal cells in the mitochondrial protein-lipid complex. See Margoliash and Schejter (1966) Advan. Protein Chem.
  • Cytochrome c can be iontophoretically transported readily across human or mouse skin. See (1993) "Electrotransport: A Technology whose Time Has Come”.
  • proteins that complex metal ions, and particularly iron, such as siderophores, enterobactin, HBED (N,N'-bis(2-hydroxybenzyl) ethylenediamine-N,N'-diacetic acid), and ferrioxamines see, e . g . , Kirk-Othmer Encyclopedia of Chemical Technology, 3rd Ed., Vol. 13, pages 782-786; proteins with covalently attached heme or porphyrin groups; and other compounds covalently attached to heme or porphyrin groups will also find use as chemical modifiers in the methods described herein.
  • Aminosteroids also can be employed as chemical modifiers.
  • squalamine an antimicrobial about as potent as ampicillin, possesses three quaternary ammonium groups, a sulfate group, as well as a hydroxyl group.
  • squalamine could serve as a penetration enhancer, as well as a chemical modifier and/or a
  • chonemorphine ( (3 ⁇ ,5 ⁇ ,2OS)-N 20 ,N 20 -dimethylpregnane-3,2-diamine) possesses two amino groups, one of which can be derivatized to produce the corresponding ammonium salt, while the other can be coupled to a pharmaceutical agent.
  • conessine (3 ⁇ -(dimethylamino) con-5-enine) is a naturally occurring plant steroid having two amino groups and can find use as a chemical modifier according to the methods described herein. iv.
  • Negatively Charged Chemical Modifiers carry negative charges.
  • the negative charge typically arises from a sulfate group, a phosphate group, or a carboxy group.
  • the sulfate and carboxy groups will provide a single negative charge, whereas the phosphate group may impart either a single or double negative charge.
  • Taurine is a particularly versatile chemical modifier in that it can provide either a negative or positive charge.
  • Taurine (2-aminoethanesulfonic acid, available from Aldrich Chemical Co.) acquires a negative charge by deprotonation of its sulfonic acid group to form the corresponding sulfonate salt.
  • Taurine also possesses an amino group as chemical functionality. This amino group may be converted to the corresponding ammonium salt to provide a positive charge.
  • cysteic acid (3-sulfoalanine, available from Aldrich Chemical Co.) which possesses both amino and carboxy functionalities in addition to the sulfonic acid group, may provide either positive or negative charge.
  • sulfate salts may be produced through the reaction of a hydroxyl containing compound with sulfur trioxide and its amine and ether adducts, chlorosulfonic acid, sulfonic acid, or sulfuric acid. See, e.g., Barton and Ollis, Comprehensive Organic Chemistry. Pergamon Press, New York (1979).
  • Phosphates may be produced through the reaction of a hydroxyl containing pharmaceutical agent, chemical modifier or spacer group with phosphonyl halides, orthophosphoric acid, or phosphorus pentoxide. See, e.g., Barton and Ollis, Comprehensive Organic Chemistry.
  • Preferred examples of negatively charged pharmaceutical agent-modifier complexes include digitoxigenin-3-sulfate, triethylammonium salt; digitoxin-4'''-sulfate, triethylammonium salt; and the like. v. Nucleotide-based Chemical Modifiers
  • Nucleotides are phosphate esters of glycosides of heterocyclic bases and are the structural units of both oligonucleotides and nucleic acids. Each phosphate functionality found in a nucleotide, oligonucleotide, or nucleic acid potentially is capable of imparting a negative charge to the molecule.
  • a hydroxyl group of a sugar residue, an amino group from a base residue, or a phosphate oxygen of the nucleotide will be utilized as the needed chemical
  • the nucleotide-based chemical modifier can be prepared by conventional techniques.
  • the hydroxyl group of the sugar residue can be converted to a mercapto or amino group using techniques well known in the art.
  • the chemical modifier exhibits therapeutic effects apart from its carrier function and comprises an antisense compound or triple helix drug.
  • the nucleotide-based chemical modifier will be covalently coupled to the pharmaceutical agent via a spacer group.
  • a spacer group An illustrative embodiment calls for the use of the spacer group 3-maleimidobenzoic acid, as shown below.
  • the 5'-terminal phosphate group of the oligonucleotide is modified to produce the corresponding amin ⁇ alkyl phosphate ester.
  • the spacer group, 3-maleimidobenzoic acid is then introduced via reaction of the amino group of the phosphate ester with 3-maleimidobenzoic acid N-hydroxysuccinimide ester.
  • Pharmaceutical agents containing a mercapto group or a hydroxyl group can be covalently coupled to the spacer group through this functionality.
  • This coupling motif is particularly preferred for peptide and protein drugs containing cysteine residues which can be coupled to the spacer group through the mercapto functionality of the cysteine residue. See, e.g., Tung et al (1991) Bioconj. Chem. 2:464.
  • Aminoalkyl phosphate derivatives of nucleotide-based chemical modifiers also can be covalently coupled to pharmaceutical agents containing carboxy groups or hydroxyl groups.
  • the chemical functionality of the pharmaceutical agent is activated prior to coupling with the chemical
  • modifier e.g., an activated ester is produced from the carboxy group or a chloroformate is formed from the hydroxyl group
  • an activated ester is produced from the carboxy group or a chloroformate is formed from the hydroxyl group
  • the 5'-terminal phosphate group of the oligonucleotide is modified to produce the corresponding mercaptoalkyl phosphate ester, as shown below.
  • the mercapto group can be coupled directly to another mercapto group of a pharmaceutical agent (e.g., a mercapto group from a cysteine residue in a protein/peptide drug) via a disulfide linkage or the mercapto group can be coupled to a spacer group, such as 3-maleimidobenzoic acid, which has been previously been linked to a pharmaceutical agent (e.g., via a hydroxy, mercapto, or amino group of the pharmaceutical agent). See, generally, Eritja et al. (1991) Tetrahedron 47:4113.
  • the chemical functionality of the pharmaceutical agent is activated prior to coupling with the chemical modifier (e.g., an activated ester is produced from the carboxy group or a chloroformate is formed from the hydroxyl group) as shown below.
  • the chemical modifier e.g., an activated ester is produced from the carboxy group or a chloroformate is formed from the hydroxyl group
  • One protecting group of the precursor is removed to yield a reactive group that can be exploited for synthesis of the peptide/protein drug.
  • the second protecting group is then removed to allow for oligonucleotide synthesis.
  • Cleavage from the substrate yields a pharmaceutical agent-nucleotide-based chemical modifier complex wherein the pharmaceutical agent is a peptide/protein drug and the spacer comprises a negatively charged phosphate group.
  • a pharmaceutical agent- chemical modifier complex can be produced wherein the
  • pharmaceutical agent is a nucleotide-based drug.
  • PCR The most commonly used in vitro DNA amplification method is PCR.
  • Alternate amplification methods include, for example, nucleic acid sequence-based amplification (Comptom (1991) Nature 350:91-92) and amplified antisense RNA (Van).
  • covalently binding to a given pharmaceutical agent can be identified using a variety of screening techniques, including the screening procedures set forth in copending application Serial Nos. 07/762,522, 07/946,239, 07/778,223, 07/876,288, 07/946,239, and 07/963,321, Fodor et al. (1991) Science 251:767-773, PCT publication No. WO 92/10092, and PCT
  • a library comprising chemical modifiers will first be synthesized to screen for transport activity.
  • this library will be synthesized in a solid-state format with each modifier bound to a substrate via a cleavable linker.
  • the compound are then cleaved from the substrate and screened in vitro as to their transport characteristics.
  • the optimal modifiers are amplified, for example, in the case of nucleotide-based chemical modifiers, by PCR or other means well known to those skilled in the art, to provide sufficient chemical modifier to be accurately sequenced. Once the optimal chemical modifier is identified, the screening
  • the chemical modifier array will be bound to a solid substrate.
  • This format allows for the rapid and efficient synthesis and screening of the modifiers.
  • solid phase substrates include synthesis resins (see, e.g., Merrifield (1963) J. Am. Chem. Soc. 85: 2149-54; U.S. patent application Serial No.
  • the solid substrate can be composed of any of a wide variety of
  • materials for example, polymers, plastics, resins, polysaccharides, silicon or silica-based materials, carbon, metals, inorganic glasses, and membranes.
  • polypeptides are described, for example, in Solid Phase
  • Some embodiments will exploit a soluble array of chemical modifiers or pharmaceutical agent-chemical modifier complexes. These soluble collections can be prepared directly or, in some embodiments, a solid support is used to synthesize a library or array of chemical modifiers or complexes of diverse length and composition. The members of the library are cleaved from the support prior to use.
  • the pharmaceutical agent prior to forming the linkage between the chemical modifier, the pharmaceutical agent and optionally, the spacer group, at least one of the chemical functionalities will be activated.
  • the chemical functionalities including hydroxy, amino, and carboxy groups
  • a hydroxyl group of the chemical modifier or pharmaceutical agent can be activated through treatment with phosgene to form the
  • the hydroxyl functionality is part of a sugar residue, then the hydroxyl group can be activated through reaction with di-(n-butyl) tin oxide to form a tin complex.
  • Carboxy groups may be activated by conversion to the corresponding acyl halide. This reaction may be performed under a variety of conditions as illustrated in March, supra pp. 388-89. In a preferred embodiment, the acyl halide is prepared through the reaction of the carboxy containing group with oxalyl chloride. D. Methods of Linking
  • the pharmaceutical agent is linked covalently to a chemical modifier using standard chemical techniques through their respective chemical functionalities.
  • the chemical modifier or pharmaceutical agent can be coupled to the pharmaceutical agent through one or more spacer groups.
  • the spacer groups can be equivalent or
  • the chemical modifiers can be equivalent or different.
  • the pharmaceutical agent-modifier complex is prepared by linking a pharmaceutical agent to a chemical modifier (or optionally to a spacer group which has been or will be attached to a chemical modifier) via their respective chemical functionalities.
  • a pharmaceutical agent e.g., chemical functionality l
  • the pharmaceutical agent is joined to the chemical modifier, optionally via a spacer group, (e.g., chemical functionality 2) via the linkages shown in Table 3.
  • spacer group e.g., chemical functionality 2
  • the chemical functionalities shown in Table 3 can be present on the pharmaceutical agent, spacer, or chemical modifier, depending on the synthesis scheme employed.
  • Ketal type linkages may be produced.
  • Ketal type linkages that may be produced in the pharmaceutical agent-chemical modifier complexes of the present invention include, but are not limited to, imidazolidin-4-ones, see
  • nucleotides or nucleic acids are generally well known in the art. These processes are described in the patent and other literature. See, for example, U.S. Patent Nos. 4,431,739 and 5,013,653. Additionally, nucleic acid construction principles can be exploited using various restriction enzymes which make sequence specific cuts in the nucleic acid to produce blunt ends or cohesive ends, DNA ligases, enzymatic addition of single-stranded ends to blunt-ended DNA, and construction of synthetic DNAs by assembly of short oligonucleotides.
  • pharmaceutical agents may be formed by the reaction of an aldehyde containing chemical modifier or spacer group with the terminal amino acid of the pharmaceutical agent.
  • This cyclic derivative serves to stabilize the pharmaceutical agent towards enzymatic action, yet is easily hydrolyzed to release the peptide drug.
  • This linkage is shown below wherein R 1 , R 2 , and R 3 are independently hydrogen, alkyl, arylalkyl, aryl, and heteroaryl. H. Bundgaard (1991) Drugs of the Future.
  • Preferred examples of pharmaceutical agent-chemical modifier complexes linked via an ester include: 3 ⁇ -hydroxy-5 ⁇ -pregnan-20-one 3 ⁇ -(O-palmityl)-L-carnitine ester; 3 ⁇ -hydroxy-5 ⁇ -pregnan-20-one 3 ⁇ -(O-acetyl)-L-carnitine ester;
  • a preferred example of a pharmaceutical agent-chemical modifier complex with a carbamate linkage is 17 ⁇ - hydroxy-estra-1,3,5(10)- trien-3-yl 2-(N,N,N-trimethyl-amino)ethoxycarbonylmethyl carbamate, iodide salt.
  • Preferred examples of pharmaceutical agent-chemical modifier complexes using a spacer group include: 3-hydroxy-estra-l,3,5(10)-trien-17 ⁇ -yl 2-(N,N,N-triethylamino) ethoxycarbonylmethyl carbamate, iodide salt; indomethacin 2-[N-(6'-N',N'-dimethylamino)hexanamido]-ethyl ester; indomethacin 2-[N-methyl-N-(6'-N',N'-dimethylamino)-hexanamido]ethyl ester; indomethacin 2-[N-(6'-N',N',N'-trimethylamino)-hexanamido]ethyl ester, iodide salt; indomethacin 2-[N-methyl-N-(6'-N',N',N'-trimethyl-amino)hexanamido
  • model compounds useful in evaluating the methods described herein include 2-(4-nitrophenyl)ethylamine3-(O-acetyl)-L-carnitine amide, chloride salt; 2-(4-nitrophenyl)ethylamine choline carbamate, chloride salt; 2-(4-nitrophenyl)ethanol choline carbonate ester, chloride salt; 4-(4-nitrophenyl)cyclohexanol choline carbonate ester, iodide salt; 2-[4-(4-methoxyphenyl)butyramido]ethyl O-acetyl-L-carnitinate, chloride salt; 2-[4-(4-methoxyphenyl)butyramido]ethyl O-acetyl-L-carnitinthioate, chloride salt; 2-(4-nitrophenyl)ethanol 6-(O-acetyl-L-carnitinamido))-hexanoateest
  • One or more spacer groups optionally may be introduced between the chemical modifier and the
  • Spacer groups contain at least two chemical functionalities and, as opposed to chemical
  • modifiers do not carry a charge.
  • one chemical functionality of the spacer group bonds to a chemical
  • spacer groups examples include hydroxy, mercapto, carbonyl, carboxy, amino, ketone, and mercapto groups. Spacer groups may also be used in
  • the spacer groups may be different or equivalent.
  • the spacer can serve to introduce additional
  • pharmaceutical agent-chemical modifier complex Generally, the additional mass and functionality will affect the serum half-life and other properties of the pharmaceutical agent-chemical modifier complex. Thus, through careful selection of spacer groups, pharmaceutical agent-chemical modifier
  • Table 4 lists the serum half-lives for several model compounds and two representative pharmaceutical agent-chemical modifier complexes using an in vitro assay system described in the Experimental section below.
  • the serum half-lives will vary in vivo depending upon the age and health condition of the patient.
  • Each complex comprises a model compound or a pharmaceutical agent, a spacer group, and a chemical modifier.
  • Many of the model compounds utilize 4-nitrophenyl(ethanol, propanol, or cyclohexanol) or 4-nitrophenylethylamine as the "model" pharmaceutical agent.
  • a more complete listing of serum half-lives may be found in the Experimental section below.
  • the number of carbons in a spacer group has an effect on the serum half-life of the complex.
  • 2-(4-nitrophenyl) ethanol 6- (O-acetyl-L-carnitinamido) hexanoate ester, chloride salt, which utilizes 6-aminohexanoic acid as its spacer group has a serum half-life of 7.9 seconds.
  • 2- (4-nitrophenyl) ethyl 3-(O-acetyl-L-carnitinamido)-propanoate one can extend the half-life to 5.5 minutes.
  • 1-(4-nitrophenyl)-2-propanol 6-(O-acetyl-L-carnitinamido)-hexanoate ester contains 6-aminohexanoic acid as its spacer group. This spacer group is linked to the pharmaceutical agent via an ester linkage.
  • the half-life for 1-(4-nitrophenyl)-2-propanol 6-(O-acetyl-L- carnitinamido) hexanoate ester is 21.4 minutes. If the spacer group is changed to 6-aminohexanol and the spacer group is linked to the pharmaceutical agent via a carbonate linkage, then the serum half-life becomes 3.5 minutes.
  • a functionality modifier is a chemical entity which possesses at least one chemical functionality which can be covalently bound to the
  • pharmaceutical agent-chemical modifier complex (optionally via a spacer group), which does not necessarily carry a charge, and which serves to affect or modify a chemical, physical, or biological property of the complex, including providing a means for detection, for increasing the excretion half-life of the pharmaceutical agent, for targeting the pharmaceutical agent, for increasing avidity, for decreasing aggregation, for decreasing the inflammation and/or irritation accompanying the delivery of the pharmaceutical agent across membranes, and for facilitating receptor crosslinking.
  • chemical modifiers constitute a species within the broader class of functionality modifiers.
  • the functionality modifier can be bound to either the pharmaceutical agent, a chemical modifier, or a spacer group.
  • a chemical modifier and a functionality modifier are used, because the chemical modifier is cleaved from the pharmaceutical agent-chemical modifier complex after membrane transport, the functionality modifier will be covalently coupled to the pharmaceutical agent or the spacer group.
  • An example of a functionality modifier which serves to provide a means for detection is a radiolabeling site, including radiolabeled chelates for cancer imaging or
  • radiotherapy and for assessing dose regiments in different tissues, such as kemptide.
  • modifiers are capable of extending the excretion half-life of a pharmaceutical agent.
  • these modifiers will find use with peptide and protein drugs or other pharmaceutical agents with short excretion half-lives.
  • this modifier will comprise a moiety capable of binding to a serum protein, such as human serum albumin.
  • those moieties will be bound to plasma more than 60%, preferably more than 70%, more
  • effector groups include naproxen, fluoxetine, oxazepam, nitrazepam, phenylbutazone, nortriptyline, methadone
  • hydrochloride hydrochloride, lorazepam, imipramine, haloperidol, flurazepam, doxycycline, ditonin, diflunisal, diazoxide, diazepam,
  • nordazepam desipramine, dapsone, clofibrate, amantadine, chlorthalidone, clonazepam, chlorpropamide, chlorpromazine, chlorpheiramine, chloroquine, carbamazepine, auranofin, amitriptyline, amphotericin B, piroxicam, warfarin, pimozide, doxorubicin, pyrimethamine, amidoarone, protriptylene,
  • functionality modifier will comprise a circulating carrier protein, for example, an antibody, or antigen-binding
  • the antibody, fragment, or derivative thereof should have a relatively long half-life in the circulation, generally on the order of about 1-24 hours, and preferably about 12-24 hours. Because the half-lives of antibody fragments are generally shorter than that of intact antibodies, it may be necessary to increase the half-life of the fragments by attaching polyethylene glycol or polyamino acid chains to the fragment.
  • the functionality modifier will serve as a "targeting" modifier and serve to increase tissue or organ specificity, increase the local concentration of drug in the target tissue, or intracellular or
  • this type of “targeting” modifier will comprise a peptide that binds to a cell surface receptor and preferably, peptides that bind to an internalized receptor, such as transferrin.
  • the simultaneous use of two different targeting modifiers could result in greater specificity as well as high avidity.
  • the targeting modifier can also serve to "target” or direct the pharmaceutical agent-chemical modifier complex inside a cell, i.e., to achieve internalization of the
  • endocytotic vesicles generally fuse with acidic vesicles wherein ligand-receptor dissociation occurs at low pH.
  • acid vesicles contain diverse hydrolytic enzymes including esterases and proteases.
  • endothelial cells that engage in transcellularly directed molecular trafficking.
  • directed movement of peptides across gut epithelial cells involves several
  • the transcytotic movement of endocytotic vesicles across the endothelial cells constituting the blood-brain barrier is a similar process, yielding a net flux of endocytosed molecules from the blood to the brain compartment.
  • direction of a pharmaceutical agent to an intracellular vesicle compartment via receptor-mediated endocytosis can represent a route for drug effects on the epithelial/endothelial cell, as well as a route for drug transport across otherwise drug impermeable cell monolayers.
  • a cell internalization modifier typically will comprise a receptor specific targeting modifier, for example, folic acid or folate, which is implicated in receptor mediated
  • derivatives of domain II of Pseudomonas exotoxin can be used to transport the pharmaceutical agent-chemical modifier complex from vesicles into the cytoplasm.
  • Functionality modifiers can also serve to increase the avidity of receptor binding.
  • a dimerization peptide such as the peptide linker SKVILF will be used.
  • Formation of the high-avidity dimer will occur preferentially on tissues with high receptor concentration and thus, will also provide additional specificity for tissues with high receptor densities.
  • a receptor crosslinking functionality modifier is essentially a targeting modifier.
  • Crosslinking of cell surface receptors is a useful ability for a pharmaceutical agent in that crosslinking is often a required step before receptor internalization.
  • the crosslinking modifier can be used as a means to incorporate a pharmaceutical agent into a cell.
  • the presence of two receptor binding sites i.e., targeting modifiers gives the pharmaceutical agent increased avidity.
  • each pharmaceutical agent will have a targeting modifier and an avidity modifier (i.e., a dimerization peptide).
  • an avidity modifier i.e., a dimerization peptide
  • crosslinking specificity can be obtained for tissues with high receptor density.
  • a functionality modifier may serve to prevent aggregation.
  • many peptide and protein pharmaceutical agents form dimers or larger aggregates which may limit their permeability or otherwise affect
  • the hexameric form of insulin can be inhibited through the use of an appropriate functionality modifier and thus, result in greater diffusability of the monomeric form of insulin.
  • Bi- and multi-functional chemical modifiers and multi-functional spacer groups are particularly preferred in that they provide an additional means of altering the
  • the derivatization may occur either prior to or after coupling of the chemical modifier or spacer group to the pharmaceutical agent.
  • Carnitine is a particularly preferred bifunctional chemical modifier because of the ease with which its
  • derivatization may be accomplished.
  • the hydroxyl group of carnitine may be utilized in a reaction with fatty acids of varying chain lengths.
  • the carboxy group may then be exploited to form a bond with a pharmaceutical agent.
  • An example of a pharmaceutical agent-chemical modifier complex containing a derivatized carnitine is digitoxigenin-3-(O-palmitoyl-L-carnitine) ester, chloride salt which contains the palmitoyl derivative of carnitine.
  • Functionalities which may need to be protected include, but are not limited to, hydroxy, mercapto, amino, and carboxy groups.
  • protecting groups may be used to block or protect a chemical functionality.
  • the choice of protecting group will depend on many factors including sensitivity of the molecule to reaction conditions and other functionality in the molecule.
  • the protecting group may be chosen for its effect on serum half-life of the resulting pharmaceutical agent-chemical modifier complex. Examples of protecting groups and techniques for protection and deprotection can be found in Greene et al . Protective Groups in Organic Svnthesis. 2nd Ed., John Wiley & Sons: New York (1991), which is
  • the pharmaceutical agent-chemical modifier complex may be produced using either chemical or biochemical
  • Biochemical techniques are used primarily in the case of protein drugs and include recombinant expression methods.
  • the pharmaceutical agent is linked to a chemical modifier using standard chemical techniques through their respective chemical functionalities.
  • the chemical modifier or pharmaceutical agent may be coupled to a spacer group prior to formation of the pharmaceutical agent-chemical modifier complex.
  • the complex may be represented as pharmaceutical agent-[(spacer) x -(chemical modifier) y ] z or A-(S ⁇ -M y ) z wherein x is 0-10, y is y-10 and z is 1-10 and A is the pharmaceutical agent, S is the spacer group and M is the chemical modifier.
  • the spacer groups may be equivalent or different when used in combination.
  • the chemical modifiers may be equivalent or different.
  • at least one functionality modifier will also be covalently linked, optionally via a spacer group(s), to the pharmaceutical agent, chemical modifier, and/or spacer group.
  • the ratio of pharmaceutical agent to chemical modifier can be about 1:10 (i.e., y is 10). to about 1:5 (i.e., y is 5), and most preferably, about 1:1 (i.e., y is 1).
  • the pharmaceutical agent-chemical modifier complex will have a molecular weight of less than about 50,000, more often less than about 25,000 daltons, and most preferably, less than about 15,000 daltons.
  • the pharmaceutical agent has more than one chemical functionality, it can be coupled to more than one chemical modifier.
  • a bis-adduct will result if the
  • pharmaceutical agent binds to two molecules of a single chemical modifier.
  • a pharmaceutical agent may bind with several different chemical modifiers.
  • This might best be accomplished through a sequential coupling scheme. For example, one of the chemical functionalities of the pharmaceutical agent is first
  • a chemical modifier is then joined to the remaining chemical functionalities of the pharmaceutical agent.
  • the protecting group on the pharmaceutical agent is removed to release the chemical functionality which may then be coupled to a second chemical modifier.
  • Preferred examples of bis adducts include piroxicam-N,O-bis (choline chloride) carbonate ester;
  • Many protein drugs including INF- ⁇ 2 or chemical modifiers are manufactured in recombinant expression systems. These recombinant systems allow for the introduction or deletion of charged (positively or negatively) residues from the protein thus, allowing for enhanced transport and delivery of the modified protein through membranes without requiring the attachment of a separate chemical modifier.
  • charged residues are as N- or C- terminal tails. These could be designed to be labile to proteases in the skin or serum, effecting the removal of the charged tail after delivery.
  • mature insulin results from two discreet processing steps, from preproinsulin to proinsulin to mature insulin.
  • the conversion of proinsulin to the mature form is
  • the prodrug i.e., proinsulin
  • the active drug i.e., insulin
  • fusion protein consisting of the pharmaceutical agent covalently bound to various highly charged peptides can be produced. This can be achieved by fusing the cloned gene encoding the pharmaceutical agent to a segment that encodes a charged peptide residue containing several charged (positively or negatively) amino acids. These charged peptide residues would be rich in lysine, arginine and/or histidine. The net charge on the residues, as well as the charge distribution and localization, can be varied.
  • the actual genetic constructs engineered for expression may incorporate oligonucleotides encoding the recognition sequence from maltose binding protein joined to the desired fusion protein by a bond that can be cleaved after passage through a column of immobilized maltose. See U.S. application No. 07/876,288, filed April 29, 1992, which is incorporated herein by
  • protein drugs or chemical modifiers which contain a plurality of charged residues may be
  • Enzymes also can be employed as a means for
  • the enzyme will comprise an esterase, i.e., an hydrolase that can convert an ester into an acid residue and an alcohol residue.
  • the acid may be a carboxylic, a phosphoric, or a sulfuric acid; and the ester may be an alcoholic or a thiol ester.
  • a protein or peptide drug i.e., the acid residue
  • an esterase such as cholinesterase
  • a large excess of the alcohol residue such as choline.
  • a large excess of the alcohol residue is utilized to drive the equilibrium towards ester formation thus, incorporating the alcohol residue.
  • ester formation will result in the introduction of charge to the protein or peptide drug and hence, the enhancement of the drug's transport and delivery through membranes.
  • this method will be applicable with any enzyme capable of posttranslational modification of a protein and can result in either the introduction of positive charge or the deletion of negative charge.
  • enzymes include, but are not limited to, those enzymes
  • prosthetic groups e.g., the attachment of carbohydrates toglycoproteins.
  • transfection techniques and equally conventional techniques for cloning and subcloning DNA may also be used and are known to those of skill in the art.
  • Various types of vectors may be used such as plasmids and viruses including animal viruses and bacteriophages.
  • the vectors may exploit various marker genes which impart to successfully transfected cells a detectable phenotypic characteristic that can be used to identify which of a family of cells has successfully incorporated the
  • recombinant DNA of the vector The production of various proteins of interest may be achieved by expressing fused protein which is collected, purified, and then cleaved to remove the extraneous portion of the molecule.
  • invention provides pharmaceutical agent-chemical modifier complexes with a charge-to-mass ratio that allows the complex to be delivered in therapeutically effective amounts.
  • the charge-to-mass ratio of such a complex will be equal to or exceed one charge per 5000 daltons.
  • the charge-to-mass ratio will be equal to or exceed one charge per 2500 daltons.
  • the charge-to-mass ratio will be equal to or exceed one charge per 1000 daltons.
  • the pharmaceutical agent-modifier complex can be admixed with an acceptable physiological carrier, such as water, aqueous alcohols, propylene glycol, dimethylsulfoxide, to make a composition suitable for contact with the various membranes and transport and delivery through these membranes.
  • an acceptable physiological carrier such as water, aqueous alcohols, propylene glycol, dimethylsulfoxide
  • the composition may contain other materials such as dyes, pigments, inert fillers, or other permeation enhancers, excipients, and conventional components of
  • the activity of the pharmaceutical agent-modifier complex may be ascertained through studies of the hydrolytic or enzymatic conversion of the complex to the unbound
  • the in vitro skin permeation rate of a pharmaceutical agent-chemical modifier complex can be measured using flow-through diffusion cells. Typically these cells will have an active area of 1 cm 2 and a receiving volume of 3 ml.
  • the receptor fluid generally isotonic saline, is pumped into and through the cells, by a peristaltic pump. Samples are collected in glass vials arranged in an automatic fraction collector. Human, mouse, or porcine skin is placed on the lower half of the diffusion cell with the stratum corneum facing the donor compartment. The transdermal device is placed on the stratum corneum and the amount of drug
  • permeating across the skin ⁇ g/cm 2 ⁇ hr
  • permeating across the skin ⁇ g/cm 2 ⁇ hr
  • a solution of the complex can be placed into the donor compartment and the amount of transported drug can be calculated.
  • the electrotransport behavior of the charged complex in comparison with the pharmaceutical agent may also be assessed using the above analytical techniques and gel or capillary electrophoresis.
  • the complex merits further study for improved iontophoretic transdermal deliverability.
  • Preparation measurements may also be performed on excised skin in conventional diffusion cell tests. See Lattin et al .
  • compositions described herein will find use in the treatment of a variety of diseases, including but not limited to those described below.
  • pharmaceutical agents can be designed to prevent expression of diverse potential target genes,
  • oncogenes including oncogenes, fungal genes, and any other gene known to be activated specifically in the skin.
  • These pharmaceutical agents can then be delivered directly to melanomas, Kaposi sarcomas, psoriasis lesions, and fungal infected skin, and the like.
  • the complexes described herein will find use in the treatment of viral, fungal, and bacterial infections of the skin and mucous membranes, including genital warts caused by the human papilloma virus and infections caused by Herpes viruses.
  • the present invention provides for the delivery of therapeutic compositions of pharmaceutical agent- chemical modifier complexes directly to block mediators of inflammation, including cytokines, growth factors, cell adhesion molecules or their ligands and receptors thereof, as well as key enzymes in pathways leading to inflammation. More specifically, these blocking actions include preventing the expression of cytokines (such as IL-1), growth factors (such as TGF- ⁇ and EGF), or cell adhesion molecules (such as ELAM and ICAM); or the receptors for cytokines (such as IL-1), growth factors, or cell adhesion molecules.
  • cytokines such as IL-1
  • growth factors such as TGF- ⁇ and EGF
  • cell adhesion molecules such as ELAM and ICAM
  • Key enzymes whose expression may be blocked include protein kinase C and
  • the complexes described herein can be used to treat conditions in which improper immune or inflammatory responses have been implicated such as psoriasis (e.g., by blocking the expression of IL-1, TGF ⁇ , amphiregulin, or IL-6); atopic dermatitis and eczema (e.g., by blocking the overexpression of IgE); rheumatoid arthritis; allergic rhinitis (e.g., by blocking the expression of IL-4); and the like.
  • psoriasis e.g., by blocking the expression of IL-1, TGF ⁇ , amphiregulin, or IL-6
  • atopic dermatitis and eczema e.g., by blocking the overexpression of IgE
  • rheumatoid arthritis e.g., by blocking the expression of IL-4
  • the complexes described herein can be used to treat conditions in which improper immune or inflammatory responses have been implicated such as p
  • squamous cell carcinoma including of the cervix
  • by blocking the expression of certain factors which promote cell growth and/or adhesion and which are believed to be involved in metastasis for example, by blocking the expression of certain factors which promote cell growth and/or adhesion and which are believed to be involved in metastasis.
  • the pharmaceutical agent-chemical modifier is the pharmaceutical agent-chemical modifier
  • Transdermal administration typically involves the delivery of a pharmaceutical agent for percutaneous passage of the drug into the systemic circulation of the patient.
  • the skin sites include anatomic regions for transdermally administering the drug and include the forearm, abdomen, chest, back, buttock, mastoidal area, and the like.
  • Transdermal delivery is accomplished by exposing a source of the complex to a patient's skin for an extended period of time.
  • Transdermal patches have the added advantage of providing controlled delivery of a pharmaceutical agent-chemical modifier complex to the body. See Transdermal Drug Delivery: Developmental Issues and Research Initiatives, Hadgraft and Guy (eds.), Marcel Dekker, Inc., (1989);
  • Such dosage forms can be made by dissolving, dispersing, or otherwise incorporating the
  • a pharmaceutical agent-chemical modifier complex in a proper medium, such as an elastomeric matrix material.
  • Absorption enhancers can also be used to increase the flux of the
  • the rate of such flux can be controlled by either providing a rate-controlling membrane or dispersing the compound in a polymer matrix or gel.
  • a simple adhesive patch can be prepared from a backing material and an acrylate adhesive.
  • the pharmaceutical agent-chemical modifier complex and any enhancer are formulated into the adhesive casting solution and allowed to mix thoroughly.
  • the solution is cast directly onto the backing material and the casting solvent is evaporated in an oven, leaving an adhesive film.
  • the release liner can be attached to complete the system.
  • a further embodiment of this invention will utilize a hydrogel matrix patch.
  • the hydrogel matrix will comprise alcohol, water, drug, and several hydrophilic
  • This hydrogel matrix can be incorporated into a transdermal patch between the backing and the adhesive layer.
  • the liquid reservoir patch will also find use in the methods described herein.
  • This patch comprises an
  • impermeable or semi-permeable, heat sealable backing material a heat sealable membrane, an acrylate based pressure sensitive skin adhesive, and a siliconized release liner.
  • the backing is heat sealed to the membrane to form a reservoir which can then be filled with a solution of the complex, enhancers, gelling agent, and other excipients.
  • Foam matrix patches are similar in design and components to the liquid reservoir system, except that the gelled pharmaceutical agent-chemical modifier solution is constrained in a thin foam layer, typically a polyurethane. This foam layer is situated between the backing and the membrane which have been heat sealed at the periphery of the patch.
  • the rate of release is typically controlled by a membrane placed between the reservoir and the skin, by diffusion from a monolithic device, or by the skin itself serving as a rate-controlling barrier in the delivery system. See U.S. Patents 4,816,258; 4,927,408; 4,904,475; 4,588,580, 4,788,062; and the like.
  • the rate of drug delivery will be dependent, in part, upon the nature of the membrane. For example, the rate of drug delivery across membranes within the body is generally higher than across dermal barriers. The rate at which the complex is delivered from the device to the membrane is most advantageously
  • rate-limiting membranes which are placed between the reservoir and the skin. Assuming that the skin is sufficiently permeable to the complex (i.e.,
  • the membrane will serve to control the dosage rate experienced by the patient.
  • Suitable permeable membrane materials may be selected based on the desired degree of permeability, the nature of the complex, and the mechanical considerations related to constructing the device.
  • Exemplary permeable membrane materials include a wide variety of natural and synthetic polymers, such as polydimethylsiloxanes (silicone rubbers), ethylenevinylacetate copolymer (EVA), polyurethanes, polyurethane-polyether copolymers, polyethylenes, polyamides, polyvinylchlorides (PVC), polypropylenes, polycarbonates, polytetrafluoroethylenes (PTFE), cellulosic materials, e.g., cellulose triacetate and cellulose nitrate/acetate, and hydrogels, e.g., 2-hydroxyethylmethacrylate (HEMA).
  • siloxanes silicone rubbers
  • EVA ethylenevinylacetate copolymer
  • PVC polyurethanes
  • polyurethane-polyether copolymers
  • compositions according to this invention may also include one or more preservatives or bacteriostatic agents, e.g., methyl hydroxybenzoate, propyl hydroxybenzoate,
  • compositions also can contain other active ingredients such as antimicrobial agents, particularly
  • the therapeutic composition will be delivered by a standard iontophoretic device.
  • iontophoresis is an introduction, by means of electric current, of ions of soluble salts into the tissues of the body. More specifically, iontophoresis is a process and technique which involves the transfer of ionic (charged) species into a tissue (for example through the skin of a patient) by the passage of a electric current through an electrolyte solution containing ionic molecules to be
  • the rate of release is primarily controlled by the voltage or current.
  • the active electrode includes the therapeutic species as a charged ion, or a precursor for the charged ion, and the transport occurs through application of the
  • electromotive force to the charged therapeutic species. If other electrotransport phenomenon are involved, then the therapeutic species will be delivered in an uncharged form, transfer being motivated, however, by electromotive force.
  • the applied current may induce movement of a non-therapeutic species, which carries with it water into the subject. The water may have dissolved therein the therapeutic species.
  • electrotransport of the non-therapeutic charged species induces movement of the therapeutic but non-charged species.
  • an appropriate potential between two electrode systems in electrical contact with the skin. If a positively charged drug is to be delivered through the skin, then an appropriate electromotive force can be generated by orienting the positively charged drug species at a reservoir associated with the anode. Similarly, if the ion to be transferred across the skin is negatively charged, then an appropriate electromotive force can be generated by positioning the drug in a reservoir at the cathode.
  • a single system can be utilized to transfer both positively charged and negatively charged drugs into a patient at a given time; and, more than one cathodic drug and/or more than one anodic drug may be delivered from a single system during a selected operation.
  • Both electrodes are disposed so as to be in intimate electrical contact with some portion (typically skin) of the subject (human or animal) typically by means of two remote electrolyte-containing reservoirs, between which current passes as it moves between the skin and the
  • One electrode is the electrode from which the pharmaceutical agent-chemical modifier complex is delivered or driven into the body by application of the electromotive force.
  • the other electrode typically referred to as an
  • electrode serves to close the electrical circuit through the body. In some instances both electrodes may be “active”, i.e. drugs may be delivered from both.
  • electrode or variants thereof, when used in this context refers to an electrically conductive member, through which a current passes during operation.
  • Electrode materials ranging from platinum to silver-silver chloride, are available for these devices. The primary difference in these materials is not in their ability to generate an electric potential across the skin, but rather in certain nuances associated with their performance of this function. For example, platinum
  • Electrodes hydrolyze water, thus liberating hydrogen ions and subsequently, changes in pH. Obviously, changes in pH can influence the ionization state of therapeutic agents and their resulting rate of iontophoretic transport.
  • Silver-silver chloride electrodes do not hydrolyze water. However, these electrodes require the presence of chloride ion which may compete for current-induced transport.
  • Electrotransport devices generally require a reservoir as a source of the species (or a precursor of such species) which is to be moved or introduced into the body.
  • the reservoir typically will comprise a pool of electrolyte solution, for example an aqueous electrolyte solution or a hydrophilic, electrolyte-containing, gel or gel matrix, semi-solid, foam, or absorbent material.
  • electrolyte solution for example an aqueous electrolyte solution or a hydrophilic, electrolyte-containing, gel or gel matrix, semi-solid, foam, or absorbent material.
  • Such pharmaceutical agent-chemical modifier complex reservoirs when electrically connected to the anode or the cathode of an iontophoresis device, provide a source of one or more ionic species for electrotransport.
  • iontophoresis devices employ a selectively permeable membrane.
  • the composition of this membrane will vary with the particular needs of the system and will depend upon the composition of the electrolyte reservoir, i.e., the nature of the pharmaceutical agent or pharmaceutical agent-chemical modifier complex, the transference of current out of the reservoir, and the desired selectivity to transport of particular types of charged and uncharged species.
  • microporous polymer or hydrogel such as is known in the art can be utilized. See, e.g., U.S. Patent No. 4,,927,408.
  • Suitable permeable membrane materials can be selected based on the desired degree of permeability, the nature of the complex, and the mechanical considerations related to constructing the device.
  • Exemplary permeable membrane materials include a wide variety of natural and synthetic polymers, such as polydimethylsiloxanes (silicone rubbers), ethylenevinylacetate copolymer (EVA), polyurethanes, polyurethane-polyether copolymers, polyethylenes, polyamides, polyvinylchlorides (PVC), polypropylenes, polycarbonates, polytetrafluoroethylenes (PTFE), cellulosic materials, e.g., cellulose triacetate and cellulose nitrate/acetate, and hydrogels, e.g., 2-hydroxyethylmethacrylate (HEMA)'.
  • buffers will also be incorporated into the reservoir to maintain the reservoir environment at the same charge as the electrode.
  • the drug may act as its own buffer.
  • variables which may effect the rate of transport include drug concentration, buffer concentration, ionic strength, nonaqueous cosolvents, and any other variables which may effect the rate of transport.
  • the circuit is completed by connection of the two electrodes to a source of electrical energy as a direct current; for example, a battery or a source of appropriately modified alternating current.
  • a source of electrical energy for example, a battery or a source of appropriately modified alternating current.
  • the positive electrode the anode
  • the negative electrode the cathode
  • the positive electrode anode
  • Chemical enhancers and electroporation can also be utilized to alter the iontophoretic transport rate.
  • the coapplication of oleic acid to the skin causes a large decrease in the skin impedance or resistance which is inversely related to permeability or transport. See Potts et al . (1992) Solid State Ionics 53-56: 165-169.
  • Solid State Ionics 53-56 165-169.
  • the delivery device can be held in place with the adhesive of the matrix, with an adhesive along the perimeter of the matrix, with tape or elastic, or any other means, so long as the device allows the pharmaceutical agent-chemical modifier complex to be transported through the skin.
  • the device can be placed on any portion of the skin or dermal surface, such as the arm, abdomen, thigh, and the like.
  • the device can be in various shapes and can consist of one or more complexes and/or transport areas.
  • the direct current is applied through moist pad-type electrodes with size corresponding to that of the skin region to be treated.
  • the interposition of a moist pad between the electrode plate and the skin is necessary for making a perfect contact, preventing any skin burns,
  • the drug is administered through an electrode having the same charge as the drug, and a return electrode opposite in charge to the drug is placed at a neutral site on the body surface. The operator then selects a current
  • One aspect of this invention provides for the topical delivery of therapeutic compositions of pharmaceutical agent-chemical modifier complexes of pharmaceutical agents.
  • This treatment regimen is suitable either for the systemic administration of the pharmaceutical agent or for localized therapy, i.e., directly to pathological or diseased tissue.
  • the topical formulations will comprise a preparation for delivering the pharmaceutical agent-chemical modifier complex directly to the affected skin comprising the complex, typically in concentrations in the range' of from about 0.001% to 10%; preferably, from about 0.01 to about 10%; more preferably, from about 0.1 to about 5%; and most
  • Topical preparations can be prepared by combining the pharmaceutical agent-chemical modifier complex with conventional pharmaceutical diluents and carriers commonly used in topical dry, liquid, cream and aerosol formulations.
  • Ointment and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • bases may include water and/or an oil such as liquid paraffin or a vegetable oil such as peanut oil or castor oil.
  • Thickening agents which may be used according to the nature of the base include soft paraffin, aluminum stearate, cetostearyl alcohol, propylene glycol, polyethylene glycols, woolfat, hydrogenated lanolin, beeswax, and the like.
  • Lotions may be formulated with an aqueous or oily base and will, in general, also include one or more of the following: stabilizing agents, emulsifying agents, dispersing agents, suspending agents, thickening agents, coloring agents, perfumes, and the like.
  • Powders may be formed with the aid of any suitable powder base, e.g., talc, lactose, starch, and the like.
  • Drops may be formulated with an aqueous base or non-aqueous base also comprising one or more dispersing agents, suspending agents, solubilizing agents, and the like.
  • Dosage forms for the topical administration of a complex of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and
  • the active compound may be mixed under sterile conditions with a pharmaceutically- acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
  • the ointments, pastes, creams and gels also may contain excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Powders and sprays also can contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can
  • hydrocarbons such as butane and propane.
  • mucosal membranes such as gastrointestinal, sublingual, buccal, nasal, pulmonary, vaginal, corneal, and ocular
  • the membrane of the buccal cavity is non-keratinized.
  • the buccal membrane is similar to the skin because both are stratified with the former consisting of polygonal cells at the basal membrane leading to squamous cells at the surface.
  • Transmucosal drug dosage forms e.g., tablet, suppository, ointment, gel, pessary, membrane, and powder
  • Transmucosal drug dosage forms are typically held in contact with the mucosal membrane and disintegrate and/or dissolve rapidly to allow immediate systemic
  • an oral formulation such as a lozenge, tablet, or capsule
  • the method of manufacture of these formulations are known in the art, including but not limited to, the addition of the pharmaceutical agent-chemical modifier complex to a pre-manufactured tablet; cold compression of an inert filler, a binder, and either a pharmaceutical agent-chemical modifier complex or a substance containing the complex (as described in U.S. Patent No. 4,806,356); and encapsulation.
  • Another oral formulation is one that can be applied with an adhesive, such as the cellulose derivative, hydroxypropyl cellulose, to the oral mucosa, for example as described in U.S. Pat. No. 4,940,587.
  • This buccal adhesive formulation when applied to the buccal mucosa, allows for controlled release of the pharmaceutical agent-chemical modifier complex into the mouth and through the buccal mucosa.
  • aerosol includes any gas-borne suspended phase of the pharmaceutical agent-chemical modifier complex which is capable of being inhaled into the bronchioles or nasal
  • aerosol includes a gas-borne
  • Aerosol also includes a dry powder composition of the pharmaceutical agent-chemical modifier complex suspended in air or other carrier gas, which may be delivered by insufflation from an inhaler device, for example.
  • concentration of the pharmaceutical agent-chemical modifier complex is 0.1-100 milligrams (mg)/
  • milliliter preferably 0.1-30 mg/ml, and most preferably, 1-10 mg/ml.
  • solutions are buffered with a physiologically compatible buffer such as phosphate or bicarbonate.
  • a physiologically compatible buffer such as phosphate or bicarbonate.
  • the usual pH range is 5 to 9, preferably 6.5 to 7.8, and more preferably 7.0 to 7.6.
  • sodium chloride is added to adjust the osmolarity to the physiological range, preferably within 10% of isotonic.
  • Solutions of the pharmaceutical agent-chemical modifier complex may be converted into aerosols by any of the known means routinely used for making aerosol inhalant
  • such methods comprise
  • pressurizing or providing a means of pressurizing a container of the solution usually with an inert carrier gas, and passing the pressurized gas through a small orifice, thereby pulling droplets of the solution into the mouth and trachea of the animal to which the drug is to be administered.
  • a mouthpiece is fitted to the outlet of the orifice to facilitate delivery into the mouth and trachea.
  • the pharmaceutical agent is coupled to the chemical modifier via a covalent bond.
  • This covalent bond may be non-reversible, partially reversible, or preferably, reversible.
  • the degree of reversibility corresponds to the ability of the pharmaceutical agent-chemical modifier complex to hydrolyze in vivo.
  • the bond will be reversible (i.e., easily hydrolyzed) or partially reversible (i.e., partially or slowly hydrolyzed). Cleavage of the bond can occur through biological or physiological processes.
  • physiological processes will cleave bonds at other locations within the complex (e.g., removing an ester group or other protecting group that is coupled to an otherwise sensitive chemical functionality) before cleaving the bond between the pharmaceutical agent and chemical modifier, resulting in partially degraded complexes; or multiple cleavages will . occur, for example, between the spacer and agent and then the spacer and modifier.
  • circulating enzymes in the plasma can be used to cleave the chemical modifier from the pharmaceutical agent.
  • These enzymes can include non-specific aminopeptidases and esterases, dipeptidyl carboxy peptidases, proteases of the blood clotting cascade, and the like.
  • cleavage may be brought about by nonenzymatic processes.
  • chemical hydrolysis may be initiated by differences in pH experienced by the complex following delivery.
  • the pharmaceutical agent-chemical modifier complex may be characterized by a high degree of chemical lability at physiological pH of 7.4, while exhibiting higher stability at an acidic or basic pH in the reservoir of the delivery device. Examples of a
  • pharmaceutical agent-chemical modifier complex which may be cleaved in such a process are those with N-Mannich base linkages.
  • Conversion of the complex to the pharmaceutical agent may also involve a combination of both enzymatic and nonenzymatic processes.
  • cleavage of the complex will occur during or shortly after transport through the skin or mucosa. However, in certain instances, cleavage is not desired until the complex reaches the pharmaceutical agent's site of action. Furthermore, in some cases, particularly with peptide and protein drugs produced via recombinant expression techniques, one may not desire cleavage of the complex. Of course, alternatively, these peptide and protein drugs can be
  • the solid was further purified by twice boiling with acetone (100 ml), cooling and filtering, and finally rinsed with acetone/ether and dried in vacuo to give 15.37 g (35.3 mmol, 87% yield, mp 164-174°C, dec. 185°C).
  • D,L-norcarnitine The methyl ester of D,L-4-dimethylamino-3-hydroxybutyric acid (D,L-norcarnitine) was prepared by
  • Digitoxigenin 300 mg, 0.8 mmol in pyridine (2.5 ml) was treated with (choline chloride) chloroformate (720 mg, 3.5 mmol) and a catalytic amount (5 mg) of 4-dimethylaminopyridine.
  • the reaction mixture was vigorously stirred and sonicated to form a viscous paste and then stirred at 40 °C for 72 hours.
  • the reaction mixture was diluted with dichloromethane (50 ml), filtered and the solid, mostly unreacted choline chloride, was washed with more
  • Fraction C (50 mg) was the purest material but all fractions contained some residual unreacted choline chloride but no unreacted digitoxin.
  • NMR 300 MHz
  • FAB MS mass spectrometry
  • O-Acetyl-L-carnitine chloride acid chloride prepared from 2.4 g (10 mmol) of O-acetyl-L-carnitine
  • Indomethacin acid chloride (430 mg, 1.2 mmol) was dissolved in chloroform (3 ml) and added to a solution of D,L-norcarnitine methyl ester (363 mg, 2.5 mmol) in chloroform (3 ml) at 0°C with stirring. The ice bath was then removed and stirring continued at room temperature for 2 hours. The reaction mixture was diluted with chloroform and extracted with saturated sodium bicarbonate. The chloroform layer was dried over sodium sulfate, filtered and rotary evaporated to give an oil which was purified by column chromatography on alumina (grade III, elution with 2.5% methanol in chloroform).
PCT/US1993/005631 1992-06-12 1993-06-11 Compositions and methods for enhanced drug delivery WO1993025197A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU45345/93A AU4534593A (en) 1992-06-12 1993-06-11 Compositions and methods for enhanced drug delivery
EP93915319A EP0647133A4 (en) 1992-06-12 1993-06-11 COMPOSITIONS AND METHODS FOR IMPROVED DRUG DELIVERY.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US89821992A 1992-06-12 1992-06-12
US07/898,219 1992-06-12
US946393A 1993-01-27 1993-01-27
US08/009,463 1993-01-27

Publications (1)

Publication Number Publication Date
WO1993025197A1 true WO1993025197A1 (en) 1993-12-23

Family

ID=26679515

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/005631 WO1993025197A1 (en) 1992-06-12 1993-06-11 Compositions and methods for enhanced drug delivery

Country Status (3)

Country Link
EP (1) EP0647133A4 (zh)
AU (1) AU4534593A (zh)
WO (1) WO1993025197A1 (zh)

Cited By (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0678297A1 (en) * 1994-02-25 1995-10-25 Bristol-Myers Squibb Company Iontophoretic transdermal delivery of deoxyspergualin compounds
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
WO1996039422A2 (en) * 1995-06-06 1996-12-12 Alza Corporation Modification of polypeptide drugs to increase electrotransport flux
WO1996039423A2 (en) * 1995-06-06 1996-12-12 Alza Corporation A method for increasing the electrotransport flux of polypeptides
EP0773719A1 (en) * 1994-07-29 1997-05-21 Emory University Compositions for targeting materials to cells containing androgen receptors
EP0796841A1 (en) * 1996-03-20 1997-09-24 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Bis alkanoyl esters of carnitine having bactericidal, fungicidal and antiprotozoal activity
US5721226A (en) * 1993-03-10 1998-02-24 Magainin Pharmaceuticals Inc. Method for inhibiting angiogenesis using squalamine and squalamine steroid derivatives
US5763430A (en) * 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US5795885A (en) * 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US5840740A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
US5840936A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US5847172A (en) * 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US5874597A (en) * 1995-06-07 1999-02-23 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
WO1999059957A1 (en) * 1998-05-15 1999-11-25 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase
US5994336A (en) * 1995-06-07 1999-11-30 Magainin Pharmaceuticals Inc. Method of inhibiting proliferation of cells by administering an aminosterol compound
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US6147060A (en) * 1996-04-26 2000-11-14 Magainin Pharmaceuticals Treatment of carcinomas using squalamine in combination with other anti-cancer agents
US6262283B1 (en) 1996-12-06 2001-07-17 Magainin Pharmaceuticals Inc. Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds
US6333189B1 (en) 1996-06-06 2001-12-25 Alza Corporation Method of making an electrotransport device
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
US6610841B1 (en) 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
WO2004067546A1 (de) * 2003-01-28 2004-08-12 Helmut Kasch Tetraalkylammoniumsalze vom kohlensäureestertyp, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6833140B2 (en) 2001-06-11 2004-12-21 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
JP2005508875A (ja) * 2001-06-29 2005-04-07 インプリクス リミテッド 転座因子として使用するためのペプチド
US6933383B2 (en) 2000-04-12 2005-08-23 Genaera Corporation Regioselective and stereoselective oxidation of fused ring systems useful for the preparation of aminosterols
US6956060B2 (en) 1990-01-03 2005-10-18 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP0814789B2 (en) 1995-03-02 2008-01-09 R.P. Scherer Technologies, Inc. Pharmaceutical compositions comprising monoamine oxidase b inhibitors
WO2008013860A2 (en) * 2006-07-28 2008-01-31 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use
JP2008530007A (ja) * 2005-02-04 2008-08-07 アメリカ合衆国 ナンドロロン17β−カーボネート
JP2010505936A (ja) * 2006-10-11 2010-02-25 テックフィールズ バイオケム カンパニー リミテッド 非常に高い皮膚浸透率を有するオキシカム及び関連化合物の正荷電水溶性プロドラッグ
JP2010516802A (ja) * 2007-01-31 2010-05-20 チョンシー ユー 皮膚浸透率の非常に高い1H−イミダゾ[4,5−c]キノリン−4−アミン及び関連化合物の正に荷電した水溶性プロドラッグ
JP2010518071A (ja) * 2007-02-13 2010-05-27 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 抗癌剤として有用な新規のカチオン性17α−置換−エストラジオール誘導体
JP2011503188A (ja) * 2007-11-14 2011-01-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ステロール修飾両親媒性脂質
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US8431576B2 (en) 2009-06-25 2013-04-30 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
US8592427B2 (en) 2010-06-24 2013-11-26 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
EP2670763A1 (en) * 2011-02-02 2013-12-11 Suzhou Neupharma Co., Ltd Certain chemical entities, compositions, and methods
US8686009B2 (en) 2009-06-25 2014-04-01 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
JP2014514300A (ja) * 2011-04-08 2014-06-19 スファエラ ファーマ ピーティーイー リミテッド 置換メチルホルミル試薬並びに化合物の物理化学的性質及び/又は薬物動態学的性質を改質するためのそれらの使用方法
CN103896791A (zh) * 2012-12-25 2014-07-02 北京蓝贝望生物医药科技股份有限公司 乙酰左卡尼汀盐酸盐的制备方法
US8795725B2 (en) 2004-11-04 2014-08-05 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
WO2014181085A1 (en) 2013-05-09 2014-11-13 Kenneth Dawson Bagshawe Tumour therapy
US8969337B2 (en) 2011-12-15 2015-03-03 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
US8993550B2 (en) 2010-01-15 2015-03-31 Suzhou Neupharma Co., Ltd. Certain chemical entities, compositions, and methods
US9018197B2 (en) 2010-08-28 2015-04-28 Suzhou Neupharma Co. Ltd. Tetradecahydro-1H-cyclopenta[a]phenanthrene compounds, compositions, and related methods of use
US9034867B2 (en) 2011-03-18 2015-05-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
US9193685B2 (en) 2012-09-19 2015-11-24 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US9340570B2 (en) 2012-04-29 2016-05-17 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9371284B2 (en) 2007-06-04 2016-06-21 Techfields Pharma Co., Ltd. Pro-drugs of NSAIAS with very high skin and membranes penetration rates and their new medicinal uses
US9452131B2 (en) 2014-03-20 2016-09-27 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
CN104151452B (zh) * 2014-07-16 2017-02-01 西北大学 聚n‑(2‑羟丙基)甲基丙烯酰胺‑氯尼达明大分子前药及其制备方法
US9872846B2 (en) 2006-07-09 2018-01-23 Techfields Pharma Co., Ltd. High penetration compositions and uses thereof
US9993556B2 (en) 2012-03-19 2018-06-12 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty glycerol esters
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
US10004807B2 (en) 2012-03-19 2018-06-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
US11135153B2 (en) 2006-07-09 2021-10-05 Techfields Pharma Co., Ltd. High penetration composition and uses thereof
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
US11541029B2 (en) 2008-12-04 2023-01-03 Techfields Pharma Co., Ltd. High penetration compositions and their applications
CN115851076A (zh) * 2022-12-21 2023-03-28 湖北航天化学技术研究所 一种石墨烯含锌防锈漆及其制备方法
US11931355B2 (en) 2022-06-29 2024-03-19 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US5085749A (en) * 1989-03-14 1992-02-04 Massachusetts Institute Of Technology Dynamically controlled membrane

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023206A1 (de) * 1979-11-02 1982-01-14 Efeka Friedrich & Kaufmann GmbH & Co KG, 3000 Hannover Indometacin-ester, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4386026A (en) * 1981-04-20 1983-05-31 Merck & Co., Inc. Cell-specific glycopeptide ligands
US4866040A (en) * 1986-01-06 1989-09-12 Alfred Stracher Aminocarnitine directed pharmaceutical agents
US5042975A (en) * 1986-07-25 1991-08-27 Rutgers, The State University Of New Jersey Iontotherapeutic device and process and iontotherapeutic unit dose
ZA882957B (en) * 1987-04-27 1989-12-27 Syntex Pharma Int Omega-quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal anti-inflammatory drugs
JPH06501448A (ja) * 1989-12-26 1994-02-17 ノバ ファーマシューティカル コーポレイション 無水物プロドラッグ組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US5085749A (en) * 1989-03-14 1992-02-04 Massachusetts Institute Of Technology Dynamically controlled membrane

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP0647133A4 *
Textbook of Biochemistry (WEST) 1966, 4th edition, see pages 169, 170. *

Cited By (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956060B2 (en) 1990-01-03 2005-10-18 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5721226A (en) * 1993-03-10 1998-02-24 Magainin Pharmaceuticals Inc. Method for inhibiting angiogenesis using squalamine and squalamine steroid derivatives
US5733899A (en) * 1993-03-10 1998-03-31 Magainin Pharmaceuticals Inc. Method for treating infection using steroid based pharmaceutical compositions
EP0678297A1 (en) * 1994-02-25 1995-10-25 Bristol-Myers Squibb Company Iontophoretic transdermal delivery of deoxyspergualin compounds
US6468981B1 (en) 1994-07-29 2002-10-22 Emory University Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors
EP0773719A4 (en) * 1994-07-29 1998-09-02 Univ Emory COMPOSITIONS FOR TARGETING MATERIALS TO CELLS CONTAINING ANDROGENIC RECEPTORS
EP0773719A1 (en) * 1994-07-29 1997-05-21 Emory University Compositions for targeting materials to cells containing androgen receptors
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US6114388A (en) * 1994-11-18 2000-09-05 Geffard; Michel Monofunctional and/or polyfunctional polylysine conjuages
WO1996015810A1 (fr) * 1994-11-18 1996-05-30 Michel Geffard Conjugues monofonctionnels et/ou polyfonctionnels de la polylysine
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
EP0814789B2 (en) 1995-03-02 2008-01-09 R.P. Scherer Technologies, Inc. Pharmaceutical compositions comprising monoamine oxidase b inhibitors
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
WO1996039423A3 (en) * 1995-06-06 1997-01-30 Alza Corp A method for increasing the electrotransport flux of polypeptides
WO1996039422A3 (en) * 1995-06-06 1997-03-06 Alza Corp Modification of polypeptide drugs to increase electrotransport flux
GB2316083A (en) * 1995-06-06 1998-02-18 Alza Corp A method for increasing the electrotransport flux of polypeptides
BE1009704A3 (fr) * 1995-06-06 1997-07-01 Alza Corp Modification de medicaments a base de polypeptide pour augmenter un flux d'electrotransport.
GB2317179A (en) * 1995-06-06 1998-03-18 Alza Corp Modification of polypeptide drugs to increase electrotransport flux
NL1003283C2 (nl) * 1995-06-06 1997-05-02 Alza Corp Modificatie van een polypeptide voor het vergroten van de elektro- transport-flux en toepassing daarvan als geneesmiddel.
US5747453A (en) * 1995-06-06 1998-05-05 Alza Corporation Method for increasing the electrotransport flux of polypeptides
NL1003284C2 (nl) * 1995-06-06 1997-03-20 Alza Corp Werkwijze voor het vergroten van de elektrotransport-flux van polypeptiden.
US7324846B2 (en) 1995-06-06 2008-01-29 Alza Corp. Method of enchancing electrontransport polypeptide flux by amino acid substitution with histidine
BE1009752A5 (fr) * 1995-06-06 1997-07-01 Alza Corp Procede pour augmenter le flux d'electrotransport de polypeptides.
GB2316083B (en) * 1995-06-06 2000-01-19 Alza Corp A method for increasing the electrotransport flux of polypeptides
FR2735132A1 (fr) * 1995-06-06 1996-12-13 Alza Corp Medicament polypeptidique modifie, composition et dispositif d'administration par electrotransport le contenant
FR2735133A1 (fr) * 1995-06-06 1996-12-13 Alza Corp Procede de preparation d'un analogue de polypeptide a electro-transportabilite amelioree a travers la peau et son utilisation
US6313092B1 (en) 1995-06-06 2001-11-06 Alza Corporation Method for increasing the electrotransport flux of polypeptides
WO1996039423A2 (en) * 1995-06-06 1996-12-12 Alza Corporation A method for increasing the electrotransport flux of polypeptides
WO1996039422A2 (en) * 1995-06-06 1996-12-12 Alza Corporation Modification of polypeptide drugs to increase electrotransport flux
GB2317179B (en) * 1995-06-06 1999-07-28 Alza Corp Modification of polypeptide drugs to increase electrotransport flux
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5994336A (en) * 1995-06-07 1999-11-30 Magainin Pharmaceuticals Inc. Method of inhibiting proliferation of cells by administering an aminosterol compound
US5874597A (en) * 1995-06-07 1999-02-23 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5763430A (en) * 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US5795885A (en) * 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US5847172A (en) * 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5840740A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
US5840936A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
EP0796841A1 (en) * 1996-03-20 1997-09-24 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Bis alkanoyl esters of carnitine having bactericidal, fungicidal and antiprotozoal activity
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
US6147060A (en) * 1996-04-26 2000-11-14 Magainin Pharmaceuticals Treatment of carcinomas using squalamine in combination with other anti-cancer agents
US6333189B1 (en) 1996-06-06 2001-12-25 Alza Corporation Method of making an electrotransport device
US6610866B2 (en) 1996-12-06 2003-08-26 Magainin Pharmaceuticals, Inc. Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds
US6262283B1 (en) 1996-12-06 2001-07-17 Magainin Pharmaceuticals Inc. Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds
US6610841B1 (en) 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
USRE40861E1 (en) 1998-05-15 2009-07-21 Sigma-Tau Industrie Farmaceutiche Reunite S.p.A. Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase
EP1484313A1 (en) * 1998-05-15 2004-12-08 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase
USRE41226E1 (en) 1998-05-15 2010-04-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase
KR100585443B1 (ko) * 1998-05-15 2006-06-02 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. 카르니틴 팔미토일-트랜스퍼라제의 활성을 가역적으로억제하는 화합물
WO1999059957A1 (en) * 1998-05-15 1999-11-25 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase
US6933383B2 (en) 2000-04-12 2005-08-23 Genaera Corporation Regioselective and stereoselective oxidation of fused ring systems useful for the preparation of aminosterols
US7728157B2 (en) 2000-04-12 2010-06-01 Ohr Pharmaceutical Inc. Regioselective and stereoselective oxidation of fused ring systems useful for the preparation of aminosterols
US6972341B2 (en) 2001-06-11 2005-12-06 Xeno Port, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7790708B2 (en) 2001-06-11 2010-09-07 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US9238616B2 (en) 2001-06-11 2016-01-19 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
US8168623B2 (en) 2001-06-11 2012-05-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6833140B2 (en) 2001-06-11 2004-12-21 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
JP2005508875A (ja) * 2001-06-29 2005-04-07 インプリクス リミテッド 転座因子として使用するためのペプチド
WO2004067546A1 (de) * 2003-01-28 2004-08-12 Helmut Kasch Tetraalkylammoniumsalze vom kohlensäureestertyp, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
US8795725B2 (en) 2004-11-04 2014-08-05 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
US8906412B2 (en) 2004-11-04 2014-12-09 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
JP2008530007A (ja) * 2005-02-04 2008-08-07 アメリカ合衆国 ナンドロロン17β−カーボネート
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US9872846B2 (en) 2006-07-09 2018-01-23 Techfields Pharma Co., Ltd. High penetration compositions and uses thereof
US11135153B2 (en) 2006-07-09 2021-10-05 Techfields Pharma Co., Ltd. High penetration composition and uses thereof
US7799829B2 (en) 2006-07-28 2010-09-21 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
WO2008013860A3 (en) * 2006-07-28 2008-03-13 Xenoport Inc Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use
US7531572B2 (en) 2006-07-28 2009-05-12 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
WO2008013860A2 (en) * 2006-07-28 2008-01-31 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use
JP2010505936A (ja) * 2006-10-11 2010-02-25 テックフィールズ バイオケム カンパニー リミテッド 非常に高い皮膚浸透率を有するオキシカム及び関連化合物の正荷電水溶性プロドラッグ
US8349866B2 (en) 2007-01-31 2013-01-08 Chongxi Yu High penetration prodrug compositions of 1H-imidazo[4,5-C]quinolin-4-amines and 1H-imidazo[4,5-C]quinolin-4-amine-related compounds
US9567329B2 (en) 2007-01-31 2017-02-14 Techfields Pharma Co., Ltd. High penetration prodrug compositions of 1H-imidazo[4,5-c]quinolin-4-amines and 1H-imidazo[4,5-c]quinolin-4-amine-related compounds and uses thereof
JP2010516802A (ja) * 2007-01-31 2010-05-20 チョンシー ユー 皮膚浸透率の非常に高い1H−イミダゾ[4,5−c]キノリン−4−アミン及び関連化合物の正に荷電した水溶性プロドラッグ
JP2010518071A (ja) * 2007-02-13 2010-05-27 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 抗癌剤として有用な新規のカチオン性17α−置換−エストラジオール誘導体
US10233198B2 (en) 2007-06-04 2019-03-19 Techfields Pharma Co., Ltd. Pro-drugs of NSAIAs with very high skin and membranes penetration rates and their new medicinal uses
US9371284B2 (en) 2007-06-04 2016-06-21 Techfields Pharma Co., Ltd. Pro-drugs of NSAIAS with very high skin and membranes penetration rates and their new medicinal uses
JP2011503188A (ja) * 2007-11-14 2011-01-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ステロール修飾両親媒性脂質
US11541029B2 (en) 2008-12-04 2023-01-03 Techfields Pharma Co., Ltd. High penetration compositions and their applications
US11518745B2 (en) 2009-06-25 2022-12-06 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
US8686009B2 (en) 2009-06-25 2014-04-01 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
US10112903B2 (en) 2009-06-25 2018-10-30 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
US8431576B2 (en) 2009-06-25 2013-04-30 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
US10351529B2 (en) 2009-06-25 2019-07-16 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
US10822306B2 (en) 2009-06-25 2020-11-03 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
US10023537B2 (en) 2009-06-25 2018-07-17 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
US10428058B2 (en) 2009-06-25 2019-10-01 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
US10723728B2 (en) 2009-06-25 2020-07-28 Alkermes Pharma Ireland Limited Prodrugs of Nh-acidic compounds
US10471078B2 (en) 2010-01-15 2019-11-12 Suzhou Neupharma Co., Ltd. Certain chemical entities, compositions, and methods
US9814735B2 (en) 2010-01-15 2017-11-14 Suzhou Neupharma Co., Ltd Certain chemical entities, compositions, and methods
US10912784B2 (en) 2010-01-15 2021-02-09 Suzhou Neupharma Co., Ltd. Certain chemical entities, compositions, and methods
US8993550B2 (en) 2010-01-15 2015-03-31 Suzhou Neupharma Co., Ltd. Certain chemical entities, compositions, and methods
US9399659B2 (en) 2010-01-15 2016-07-26 Suzhou Neupharma Co., Ltd Certain chemical entities, compositions, and methods
US10179141B2 (en) 2010-01-15 2019-01-15 Suzhou Neupharma Co., Ltd. Certain chemical entities, compositions, and methods
US8592427B2 (en) 2010-06-24 2013-11-26 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US9018197B2 (en) 2010-08-28 2015-04-28 Suzhou Neupharma Co. Ltd. Tetradecahydro-1H-cyclopenta[a]phenanthrene compounds, compositions, and related methods of use
US10766920B2 (en) 2011-02-02 2020-09-08 Neupharma, Inc. Certain chemical entities, compositions, and methods
EP3453714A3 (en) * 2011-02-02 2019-03-27 Suzhou Neupharma Co., Ltd Cardenolide and bufadienolide 3-carbonate and 3-carbamate derivatives for the treatment of cancer and compositions thereof
US10344048B2 (en) 2011-02-02 2019-07-09 Neupharma, Inc. Certain chemical entities, compositions, and methods
EP2670763A1 (en) * 2011-02-02 2013-12-11 Suzhou Neupharma Co., Ltd Certain chemical entities, compositions, and methods
EP2670763A4 (en) * 2011-02-02 2014-11-12 Suzhou Neupharma Co Ltd CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
US9493503B2 (en) 2011-02-02 2016-11-15 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9034867B2 (en) 2011-03-18 2015-05-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
US10226458B2 (en) 2011-03-18 2019-03-12 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
US9351976B2 (en) 2011-03-18 2016-05-31 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
JP2014514300A (ja) * 2011-04-08 2014-06-19 スファエラ ファーマ ピーティーイー リミテッド 置換メチルホルミル試薬並びに化合物の物理化学的性質及び/又は薬物動態学的性質を改質するためのそれらの使用方法
US8969337B2 (en) 2011-12-15 2015-03-03 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
US10004807B2 (en) 2012-03-19 2018-06-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
US9993556B2 (en) 2012-03-19 2018-06-12 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty glycerol esters
US10487108B2 (en) 2012-04-29 2019-11-26 Neupharma, Inc. Certain steroids and methods for using the same in the treatment of cancer
US11325940B2 (en) 2012-04-29 2022-05-10 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9676813B2 (en) 2012-04-29 2017-06-13 Neupharma, Inc. Certain steroids and methods for using the same in the treatment of cancer
US9340570B2 (en) 2012-04-29 2016-05-17 Neupharma, Inc. Certain chemical entities, compositions, and methods
US10065986B2 (en) 2012-04-29 2018-09-04 Neupharma, Inc. Certain chemical entities, compositions, and methods
US10639376B2 (en) 2012-09-19 2020-05-05 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US9193685B2 (en) 2012-09-19 2015-11-24 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US11097006B2 (en) 2012-09-19 2021-08-24 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US10342877B2 (en) 2012-09-19 2019-07-09 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US9861699B2 (en) 2012-09-19 2018-01-09 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
CN103896791A (zh) * 2012-12-25 2014-07-02 北京蓝贝望生物医药科技股份有限公司 乙酰左卡尼汀盐酸盐的制备方法
WO2014181085A1 (en) 2013-05-09 2014-11-13 Kenneth Dawson Bagshawe Tumour therapy
US10813928B2 (en) 2014-03-20 2020-10-27 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
US9452131B2 (en) 2014-03-20 2016-09-27 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
US10238651B2 (en) 2014-03-20 2019-03-26 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
US11406632B2 (en) 2014-03-20 2022-08-09 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
US9526726B2 (en) 2014-03-20 2016-12-27 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
US10085980B2 (en) 2014-03-20 2018-10-02 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
CN104151452B (zh) * 2014-07-16 2017-02-01 西北大学 聚n‑(2‑羟丙基)甲基丙烯酰胺‑氯尼达明大分子前药及其制备方法
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
US11931355B2 (en) 2022-06-29 2024-03-19 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
CN115851076A (zh) * 2022-12-21 2023-03-28 湖北航天化学技术研究所 一种石墨烯含锌防锈漆及其制备方法
CN115851076B (zh) * 2022-12-21 2023-10-31 湖北航天化学技术研究所 一种石墨烯含锌防锈漆及其制备方法

Also Published As

Publication number Publication date
EP0647133A4 (en) 1997-10-29
EP0647133A1 (en) 1995-04-12
AU4534593A (en) 1994-01-04

Similar Documents

Publication Publication Date Title
US5607691A (en) Compositions and methods for enhanced drug delivery
WO1993025197A1 (en) Compositions and methods for enhanced drug delivery
JP6948313B2 (ja) 治療剤の細胞内送達のための化合物および組成物
US5851548A (en) Liposomes containing cationic lipids and vitamin D
US5622712A (en) N-[ω, (ω-1)-dialkyloxy]- and N-[ω, (ω-1)-dialkenyloxy]-alk-1-yl-N, N, N-tetrasubstituted ammonium lipids and uses therefor
US5543389A (en) Covalent polar lipid-peptide conjugates for use in salves
EP0740650B1 (en) Codrugs as a method of controlled drug delivery
US5545412A (en) N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor
JP3907662B2 (ja) 自己構築ポリヌクレオチド送達システム
US9931407B2 (en) Silicon based drug conjugates and methods of using same
Foldvari et al. Dermal and transdermal delivery of protein pharmaceuticals: lipid‐based delivery systems for interferon α
JP2918693B2 (ja) 両親媒性イミダゾリニウム誘導体
US5739271A (en) Thiocationic lipids
US5711964A (en) Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
Foldvari et al. Palmitoyl derivatives of interferon α: potential for cutaneous delivery
JP5031162B2 (ja) ウイルス感染を二重ターゲティングおよびガン細胞をターゲティングするための組成物および方法
DE60014133T2 (de) Lipid zur Verwendung in einer Liposomzusammensetzung zur Abgabe eines Mittels an eine Zelle
EP2608785B1 (en) Lipomacrocycles and uses thereof
RU2275936C2 (ru) Конъюгаты и способ их получения, а также их применение для транспорта молекул через биологические мембраны
KR100691315B1 (ko) 친수성 분자를 지질화시키기 위한 방법 및 조성물
EP0747351A2 (en) Thiocationic lipids, pharmaceutical compositions and methods of use thereof
US5759519A (en) Method for the intracellular delivery of biomolecules using thiocationic lipids
US20040197390A1 (en) Neutral-cationic lipid for systemic delivery of factor VIII gene
LLOYD et al. Synthetic polymers as carriers for chemotherapeutic agents
KR20010103006A (ko) 리포좀 조성물 및 방사선민감제의 투여 방법

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1993915319

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1993915319

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1993915319

Country of ref document: EP